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ABSTRACT   
 
HIV drug resistance (HIVDR) present prior to initiating or re-initiating antiretroviral therapy 
(ART), is known as pretreatment drug resistance (PDR). Conventionally, PDR is detected by 
Sanger sequencing. Drug resistant minority variants (DRMVs) that are not reliably detected by 
Sanger sequencing can be detected by next generation sequencing. The aims of this research were 
to assess levels of PDR in HIV hyper-endemic areas (with high HIV incidence and prevalence) in 
KwaZulu-Natal (KZN) province, trends of PDR in South Africa, and the impact of DRMVs on 
ART.  
 
To assess PDR in adults from KZN hyper-endemic areas, 1845 sequences were analyzed from 
two population-based HIV surveillance studies; a longitudinal HIV surveillance programme in 
northern KZN (2013-2014), and the HIV Incidence Provincial Surveillance System (HIPSS) in 
central KZN (2014-2015). Overall, 182/1845 (10.0%) had NNRTI-PDR mutations, and when 
analyzed by study year, NNRTI-PDR was 10.2% (CI:7.5-12.9) for the HIPSS study in 2014. To 
assess PDR trends in South Africa, 6880 HIV-1 sequences were collated from 38 datasets of 
ART-naïve adults (2000-2016). Increasing levels of PDR were observed, most marked from 
2010. Crude pooled prevalence of NNRTI-PDR reached 10% in 2014, with a 1.18-fold (CI:1.13-
1.23) annual increase (p<0.001), consistent with findings from the HIPSS data. This provided the 
first evidence of high-level NNRTI-PDR in KZN and South Africa, supporting the transition to 
dolutegravir in standard first-line ART, as recommended by the World Health Organization when 
NNRTI-PDR reaches ≥10%. 
 
A case-control (2:1) study in HIV/TB co-infected adult patients was done to assess the impact of 
DRMVs at different thresholds. Cases were patients that initiated ART and had viral loads ≥1000 
copies/mL after ≥6 months on ART, and controls were those that initiated ART and achieved 
virologic suppression through 24 months. Pre-ART NNRTI-resistance was associated with ART 
failure. NGS improved detection of HIVDR at lower thresholds, but reduced the specificity of 
identifying patients at risk of virologic failure, with the specificity reducing from 97% (CI:92-99) 
at 20% threshold, to 79% (CI:71-86) at 2% threshold.  In all, the findings presented in this thesis 
provide a broad message about the need to improve quality in HIV prevention and treatment 
services.
 1 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 Background  
Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus 
(HIV). HIV is thought to have originated between 1910 and 1930 as a zoonotic transmission 
through multiple infections from non-human primates infected with Simian Immunodeficiency 
Virus (SIV) [1,2]. The theory is generally supported by the very close resemblance seen between 
certain strains of SIVs and the two types of HIV, i.e. HIV type 1 (HIV-1) and type 2 (HIV-2). For 
example, HIV-1 is highly similar to SIV in chimpanzees (SIVcpz) and HIV-2 is similar to SIV in 
sooty mangabeys (SIVsm) [1]. HIV-1 is responsible for most HIV infections globally and has four 
major groups, i.e. groups M, N, O and P [3]. Of the four groups, group M is the most common 
accounting for 95% of the pandemic [3], and has nine subtypes; A, B, C, D, F, G, H, J and K, and 
several circulating recombinant forms (CRFs), unique recombinant forms (URFs) (Figure 1) [4,5], 
as well as sub-subtypes within some of the subtypes. Most infections are due to the subtype C, 
which is responsible for approximately 50% of all HIV infections [6].  
 
 
Figure 1 Classification of HIV 
 
Since the beginning of the HIV epidemic, about 77.3 million (uncertainty bounds 59.9 million–
100 million) people have been infected by HIV and 35.4 million (25.0 million–49.9 million) have 
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people were living with HIV in 2017. As the HIV epidemic continues to grow, there have been 
more new HIV infections than deaths, with about 1.8 million (1.4 million–2.4 million) new 
infections, and 940 000 (670,000–1.3 million) HIV-related deaths, in 2017 [7]. Despite HIV 
becoming a global pandemic, East and Southern Africa are the most affected regions. There were 
approximately 800,000 (650,000–1.0 million) new HIV infections in East and Southern Africa 
alone in 2017, bringing the number of people living with HIV in the region to approximately 19.6 
million (17.5 million–22.0 million) [7], which is about 53% of the global total of people living 
with HIV. Figure 2 shows the extent of the HIV burden in the African continent in comparison to 
other continents.  
 
 
Figure 2 Global distribution of HIV in adults aged between 15 and 49 years with continent sizes 
relative to HIV burden  
(Reproduced as is from Henning B, 2016: http://www.viewsoftheworld.net/wp-
content/uploads/2016/12/HIVprevalenceMap.png)    
 
Approximately one in every three new HIV infections in the East and Southern African region in 
2017, are from South Africa [8]. The country had approximately 270,000 (240,000–300,000) new 
HIV infections in 2017 alone, with an estimated 7.2 million (6.6 million – 7.9 million) people 
living with HIV, and about 110,000 (93,000–140,000) HIV-related deaths [8]. This goes to show 
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the extent to which the HIV epidemic has affected South Africa, which now has amongst the 
highest adult HIV prevalence in the world [9] and the largest antiretroviral therapy (ART) 
programme globally [10]. Of approximately 7.2 million people living with HIV in South Africa 
by 2017, 90% (82%–>95) knew their HIV status, 61% (56–66) were on ART and 47% (43–52) 
were virally suppressed [8]. The country is not on track to achieve the 90-90-90 targets in the next 
couple of years, which means 90% of all people living with HIV knowing their HIV status, 90% 
of people with diagnosed HIV receiving sustained ART, and 90% of those on ART achieving 
virologic suppression by 2020 [11–13]. There is need for intensified efforts if South Africa is to 
achieve the targets to end the HIV epidemic by 2030. KwaZulu-Natal (KZN) is the province with 
the highest HIV prevalence in South Africa. Despite continued efforts in HIV prevention, 
treatment, and care, KZN remains the epicenter of the HIV epidemic in South Africa, with a 
prevalence as high as 27% (23.9-30.4) among adults aged 15 to 49 years, in 2017 [14]. Figure 3 
shows a map of South Africa, the overall HIV prevalence distribution, and ART coverage across 
the provinces [15], by 2015.   
 
 
Figure 3 Map of South Africa showing provincial HIV prevalence (in red text) and ART coverage 



















Figure 1 South Africa sh ing provincial HIV prevalence [14] in red and ART coverage [15] in green 






The introduction of HIV antiretroviral (ARV) drugs has been a major breakthrough in the 
prevention of new HIV infections [16,17] and in treatment of HIV [18], with the South African 
national prevalence and incidence survey suggesting reduced incidence rates between 2012 and 
2017, though they remained high among women aged 15 to 24 years [14]. Combinations of ARV 
drugs are used to form treatment regimens, and are referred to as highly active antiretroviral 
treatment (HAART), or simply as ART [19]. The World Health Organization (WHO) recommends 
life-long ART in all HIV infected people, from time of diagnosis [20]. This is supported by findings 
from two large randomized controlled clinical trials, i.e. the Strategic Timing of Antiretroviral 
Treatment (START) study [21] and the Early Antiretroviral Treatment and/or Early Isoniazid 
Prophylaxis Against Tuberculosis in HIV-infected Adults (TEMPRANO) study [22]. Both studies 
showed significant benefits to early treatment initiation compared to delayed ART. South Africa 
adopted this universal test-and-treat (UTT) approach in 2016 [23–25], with all adults that test 
positive for HIV being initiated on standard first-line ART, which includes two nucleoside reverse 
transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI), with 
protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs) reserved for second-line 
and third-line ART[26]. 
 
Despite successful implementation of the UTT strategy in the South African national ART 
program using standard ART regimens, and the consistent recommendation for treatment 
monitoring by viral load testing since the introduction of ART, the country still has high numbers 
of new HIV infections, coupled with concerns of increasing levels of drug resistant virus in ART 
naïve individuals. This underscores the dire need to strengthen the monitoring arm of the ARV 
rollout, with timely viral load testing and follow up on results, ensuring that patients are not left 
on failing ARV treatment. Accumulation of drug resistant mutations occurs in patients left on a 
failing regimen and increases the risk of transmission of drug resistant virus to ART naïve 
individuals. This translates into major public health and cost implications where patients with 
PDR are likely to experience treatment failure on standard regimens. Considering these 
challenges, the research described in this thesis aimed at assessing the levels of HIV drug 
resistance (HIVDR) in ART naïve individuals in KZN (the province with the greatest HIV 
burden) and South Africa in general, as well as exploring whether standard genotypic resistance 
testing underestimates pretreatment resistance and, if so, what is the impact of low frequency 
drug resistance mutations on clinical outcomes.  
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1.2 Literature Review 
1.2.1 HIV transmission and ART 
There are four major ways by which HIV is transmitted, that is, through sexual intercourse (i.e. 
horizontal transmission), transmission from mother-to-child (i.e. vertical transmission), through 
HIV contaminated needles and or syringes, and through transfusion with HIV-infected blood, 
blood products or organ transplant [27–29]. However, the chances of HIV transmission are 
greatly reduced when an HIV infected person is on suppressive ART, meaning that their viral 
load is at undetectable levels, as shown in the HIV Prevention Trials Network 052 (HPTN 052) 
[16] and the PARTNER study (Partners of People on ART - A New Evaluation of the Risks) [17]. 
In the HPTN 052 trial, there was a 96% reduction in HIV transmission events among 886 sero-
discordant couples that initiated ART early (at CD4 counts between 350-550 cells/mL) compared 
to those (n=877) that deferred therapy until CD4 counts were at <250 cells/mm3 (Figure 4). This 
has resulted in the use of ART as prevention, and prompted the term “U = U”, for undetectable 




Figure 4 Summary of HPTN052 trial for use of ART as prevention of HIV transmission 
(Reproduced with modifications from Kinney RG, Spach, DH (2017, August 25). Preventing HIV 
Transmission in Persons with HIV. National HIV Curriculum. (University of Washington). 




Treatment arm Study outcome
HPTN052 Trial 
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1.2.2 Antiretroviral therapy and South Africa 
ART was rolled-out in the public health sector in South Africa, in 2004 [31]. Since then, ART 
initiation guidelines have changed gradually from initiating patients with CD4 counts ≤200 
cells/μl or WHO stage IV [32], to the current UTT approach [23–25]. The preferred first-line 
regimen for late adolescents (³15 years) and adults is a combination of tenofovir (TDF) with 
emtricitabine (FTC) (or lamivudine (3TC)) and efavirenz (EFV) [33]. The South African HIV 
treatment guidelines recommend that patients on first-line ART have viral load (VL) testing done 
at ART initiation, at 6 and 12 months, and thereafter annually, if the VL remains at  <1000 
copies/mL [26]. In the case of insufficient viral suppression (i.e. VL >1000 copies/mL), intensive 
adherence counselling with repeat VL testing after 2 months is recommended. If the VL remains 
unsuppressed after intensive adherence counselling, the patient is considered as failing treatment 
and a switch to second-line ART is recommended [26]. The preferred second-line regimen for 
late adolescents and adults failing a TDF-based regimen is a combination of zidovudine, 3TC, 
and ritonavir-boosted lopinavir (LPV/r) [33]. As with first-line ART, patients with persistent 
viremia while receiving second-line ART for at least 6 months, are considered to be failing 
treatment, and only then is genotypic drug resistance testing done to select drugs for third-line 
treatment [33]. Currently, third-line ART is only administered with expert advice, is managed 
centrally by the National Department of Health third-line committee, and is based on the patient 
resistance profile and ART history [33]. 
 
Besides use of ARV drugs in life-long ART, they are also used to prevent infection in key 
populations, such as those at substantial or high risk of HIV exposure [20]. The WHO defines key 
populations as people who face social or legal challenges that make them vulnerable to HIV, such 
as adolescent girls and young women, prisoners, men who have sex with men, injection drug 
users, transgender people and sex workers [34]. Substantial risk means living in a population 
where HIV incidence is high, defined as higher than 3 per 100 person-years [20]. In such key 
populations ARV drugs are used for pre-exposure prophylaxis (PrEP) and post-exposure 
prophylaxis (PEP). PrEP is when ARV drugs are used before HIV exposure to lower chances of 
HIV infection, whilst PEP is when ARV drugs are used to prevent infection after potential HIV 
exposure, such as in cases of rape or percutaneous needle-stick injuries in healthcare workers 
[20]. The optimal use of PrEP, PEP and ART is imperative for the continued efficacy of a 
standardized regimen approach in South Africa. However, despite the significant benefits of ART 
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(as shown in the HPTN052, the START and TEMPERANO studies), its success is greatly 
threatened by development of HIVDR.  
 
1.2.3 Pre-treatment drug resistance  
HIVDR is a phenomenon where the virus mutates such that ARV drugs can not optimally inhibit 
the virus from replicating. Acquired drug resistance is the most common type of resistance, which 
occurs when the virus continues to replicate in the presence of ARV drugs. This occurs with sub-
optimal drug levels, insufficient to completely  suppress viral replication, but high enough to exert a 
positive selection pressure on the virus [35]. Low drug concentrations can be caused by factors such 
as poor treatment adherence, sub-optimal dosage and by genetic factors associated with drug 
metabolism, i.e. the cytochrome P450 genes [36,37]. HIVDR can also be a result of transmission of 
a resistant strain at primary infection, known as transmitted drug resistance (TDR), or could result 
from ART interruption and intermittent use of ART for PrEP, and PEP [38–40]. Such HIVDR in 
individuals that have not yet initiated ART, or that have prior use of ART and are re-initiating first-
line treatment is now commonly termed pre-treatment drug resistance (PDR)  [41,42].  
 
HIVDR in ART naïve patients can develop spontaneously by de novo mutagenesis. This is 
because the reverse transcriptase enzyme that converts the viral ribonucleic acid (vRNA) to 
deoxyribonucleic acid (DNA) during viral replication is error prone and lacks proof-reading 
activity [43,44]. Therefore, several viral variants are generated each day, some of which have 
drug resistant mutations. This creates a viral pool known as “quasispecies” that has drug sensitive 
and resistant virus. The drug sensitive virus (also known as wild-type virus) has greater 
replicative capacity compared to drug resistant virus [45,46]. However, once treatment is 
initiated, drug resistant virus has the ability to outcompete the wild-type virus due to drug 
selective pressure, with the ability to revert back to wild-type virus once treatment is stopped 
[35]. Figure 5 shows selection of drug resistant virus under drug pressure, and re-emergence of 




Figure 5 Selection of drug resistant virus under drug pressure, with re-emergence of wild-type virus 
after stopping ART  
(Reproduced as is from Spach, DH, Kinney RG, (2018, November 21). Evaluation and 
Management of Virologic Failure. National HIV Curriculum. (University of Washington). 
Retrieved November 2018, from https://www.hiv.uw.edu/go/antiretroviral-therapy/evalation-
management-virologic-failure/core-concept/all#hiv-drug-resistance-assays)   
 
 
Therefore, drug resistance mutations in individuals that have not yet initiated ART can result in 
inadequate viral suppression following ART initiation [47,48]. This is of great concern especially 
for drugs that have a low genetic barrier to resistance, meaning only one mutation can cause high-
level resistance to a drug, as is seen with NNRTIs [49]. Over the years, drug resistance surveys 
focused on assessing TDR in selected treatment naïve individuals, since it can be challenging to 
identify recently infected people. The WHO in the past recommended drug resistance threshold 
surveys for TDR among people who are newly diagnosed and are likely to be recently infected, 
such as people <25 years at HIV diagnosis, primigravid women, or people with known recent 
infection, who have no known exposure to ART [50,51]. With this strategy, there is a higher 
chance of sampling a high proportion of recently infected individuals among the newly diagnosed 
in countries scaling up ART.  
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However, the WHO now recommends monitoring the prevalence of PDR to NNRTIs, and 
urgently switching to first-line regimens that do not contain NNRTIs, when NNRTI-PDR has 
reached ≥10%. This is due to evidence showing increasing levels of NNRTI PDR, that are 
associated with virologic failure on first-line ART [52]. Alternatively, drug resistance testing 
should be implemented before ART initiation [41,52,53], the latter being limited by costs and 
access to the specialized test in most low and middle-income countries (LMICs) such as South 
Africa. Evidence from South Africa suggested relatively low-levels of PDR in the first decade of 
ART roll-out [54]. However, following the extensive scale-up of ART in 2010, increasing levels 
of PDR are expected, considering the increased strain on health care systems, which has resulted 
in lack of timely viral load monitoring, ART switching, and retention of patients in care [55,56]. 
Vigilant surveillance of PDR and of the evolution of HIV virulence is required, as more people 
are exposed ART [57]. 
 
1.2.4 HIV drug resistance testing 
There are two main types of HIVDR testing; phenotypic testing and genotypic testing. Phenotypic 
testing is when the virus is grown in a medium with increasing strengths of ARV drugs [49]. The 
replication of the virus is then monitored at different drug concentrations and compared to its 
replication capacity in the absence of the drug. The drug concentration required to inhibit viral 
replication by 50% (IC50) is calculated and compared to the IC50 of a reference virus as a ratio 
[49,58], and is reported as fold-resistance. An IC50 at the right of the reference virus means drug 




Figure 6 Graphs showing phenotypic drug susceptibility curves  
Graph A, shows a measure of fold resistance between wild-type/ reference virus and the patient 
viral strain; Graph B, shows a plot with the patient IC50 similar to the wild-type virus for drug 
sensitive virus; Graph C, shows a plot with the patient IC50 curve on the right for a drug resistant 
virus; Graph D, shows a plot with patient IC50 curve on the left for a virus that is hyper-susceptible 
to a drug.  
(Reproduced with modifications from Spach, DH, Kinney RG, (2018, November 21). Evaluation 
and Management of Virologic Failure. National HIV Curriculum. (University of Washington). 
Retrieved November 2018, from https://www.hiv.uw.edu/go/antiretroviral-therapy/evalation-
management-virologic-failure/core-concept/all#hiv-drug-resistance-assays)   
 
Genotypic drug resistance testing is often done using Sanger sequencing, to detect viral variants in 
relevant viral genes, such as the protease and reverse transcriptase genes. In summary, 
conventional genotypic testing involves vRNA extraction, reverse transcription to DNA, 
polymerase chain reaction (PCR) amplification and detection, PCR product purification, sequencing 
reaction, sequence reaction purification, capillary electrophoresis, sequence editing and mutation 
detection. A single nucleotide change can result in an amino acid change, which causes drug 
resistance (Figure 7). Databases such as the Stanford University HIV Drug Resistance Database 
(http://hivdb.stanford.edu) are used to determine these mutations, and provide an estimate of 
[C] Drug resistant virus
[B] Drug sensitive virus
[D] Drug hyper-susceptible virus
[A] Fold change in resistance
 11 
susceptibility as a genotypic score for each drug, based on synthesis of published data [59]. This is 
also guided by the the International AIDS Society mutation list, which is an annual updated list of 




Figure 7 Summary of genotypic HIV drug resistance testing  
(Reproduced with modifications from Spach, DH, Kinney RG, (2018, November 21). Evaluation 
and Management of Virologic Failure. National HIV Curriculum. (University of Washington). 
Retrieved November 2018, from https://www.hiv.uw.edu/go/antiretroviral-therapy/evalation-
management-virologic-failure/core-concept/all#hiv-drug-resistance-assays)   
 
Genotypic drug resistance testing by Sanger sequencing can detect mixtures of wild-type and 
resistant HIV, and it is relatively cheaper, and has faster turnaround times compared to 
phenotypic testing [61,62]. However, the Sanger sequencing (conventional sequencing) technique 
relies on sequencing the dominant viral quasispecies. Thus, Sanger sequencing detects viral 
variants that a well represented in the viral quasispecies and does not reliably detect minor viral 
variants that occur below 20% [49], i.e. variants that are not well represented in the viral pool, as 




        
Figure 8 Selective detection of well represented viral strains by conventional sequencing 
(Reproduced with modifications from Spach, DH, Kinney RG, (2018, November 21). Evaluation 
and Management of Virologic Failure. National HIV Curriculum. (University of Washington). 
Retrieved November 2018, from https://www.hiv.uw.edu/go/antiretroviral-therapy/evalation-
management-virologic-failure/core-concept/all#hiv-drug-resistance-assays)   
 
1.2.5 HIV drug resistant minority variants 
HIVDR mutations occurring at low frequencies (<20%) are called drug resistant minority variants 
(DRMVs) [63]. Although these DRMVs can not be reliably detected by Sanger sequencing, more 
sensitive point mutation technologies such as allele-specific PCR [62], oligonucleotide ligation 
assay [64], and Pan Degenerate Amplification and Adaptation [65] have the ability to detect these 
viral variants, even at 1% frequencies [62] (Figure 8). However, point-mutation assays are limited 
in the number of mutations they can detect concurrently [62]. Despite this, they have the potential 
to become point of care testing assays, as they can be used to detect signature mutations that are 
known to impact specific drugs used in ART regimens [66]. For instance, detection of three 
mutations; the K65R mutation that causes high-level resistance to TDF, the M184V mutation that 
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causes high level resistance to 3TC and increased susceptibility to TDF, and the K103N mutation 
that causes high-level resistance to nevirapine (NVP) and EFV [59], can help to assess the 
effectiveness of a typical first-line regimen that contains TDF + 3TC (or FTC) + EFV [26]. 
Therefore, point mutation assays could be relevant for use in LMICs where costs of drug 
resistance testing are a limiting factor [67,68], and at a time when point of care testing has 
become imperative [69].  
 
With advancements in technology, ultra-deep sequencing, also known as next generation 
sequencing (NGS) is becoming more popular and is slowly replacing Sanger sequencing [63]. 
NGS is highly sensitive and can sequence the whole viral genome in a single run, but the 
quantitative and qualitative reliability of the sequencing reads is directly proportional to the initial 
plasma viral load copies [70], as well as the sequencing chemistry used [63]. The cost of 
acquiring the necessary infrastructure, equipment and expertise for NGS testing remains a major 
limiting factor for the extensive use of NGS in LMICs. Also, the amount of data generated from 
NGS is huge and creates challenges in storage and access, with data analysis pipelines not well 
defined for diagnostic testing [63]. Despite the ability to detect and quantify DRMVs, the clinical 
relevance of the low frequency mutations in guiding the use of ART is not well understood. For 
instance, the effect of a mutation at a certain frequency may vary based on the drug class barrier 
to resistance, and it might be more relevant to quantify the viral load of drug resistant virus (i.e. 
the mutational load) rather than the entire viral pool, as there is evidence suggesting a dose-
dependent effect of mutational load on virologic outcomes [71]. The mutational load can be 
estimated by multiplying the frequency of the DRMV by viral load copies/mL [70]. Therefore, 
there remains a lot to be understood on the significance of DRMVs, which could be critical in 
predicting treatment response and in determining how to incorporate fast developing NGS 
technologies into current HIV treatment and monitoring practices. Details of the different NGS 
platforms, chemistries, implementation and knowledge gaps have been presented as a manuscript 
in Chapter 2 of this thesis. 
 
1.3 Problem Statement 
South Africa has had access to ARV drugs and routine viral load monitoring since public roll-out 
of ART. However, due to several weaknesses in the ART program and largely in the viral load 
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cascade, levels of PDR mutations are becoming a cause of concern, as they affect the success of 
standard ART regimens. Moreover, the impact of DRMVs on ART is not well understood.   
1.4 Research Questions 
1. What are the levels of PDR in HIV hyper-endemic settings in KZN?  
2. What are the trends of PDR in South Africa, and which mutations are responsible for these 
trends in PDR? 




These research questions are important because inadequate treatment and monitoring of HIVDR 
can result in treatment failure. One of the five strategic objectives of the Global Action plan on 
HIVDR, is to have continual monitoring and surveillance of levels of drug resistance [53]. In the 
first national PDR survey in South Africa, the overall level of surveillance PDR was 9.0% (95% 
confidence interval (CI): 6.1–13.0) [72], which would be classified as moderate resistance 
according to previous WHO guidelines [50]. A closer look at drug-class mutations showed that 
resistance was mainly driven by NNRTIs (8.3%, CI: 5.6–12.2), with NRTI (2.5% CI: 1.1-5.2) and 
PI (0.7%, CI: 0.0-2.8) resistance remaining at low-levels [72]. Another recent study in the 
Western Cape province (WC) reported moderate levels of PDR at 10%. Drug-class specific 
resistance was also higher in the NNRTIs (8.3%) and lower in the NRTIs (1.7%) and PIs (0%) 
[73]. This suggests that the increase in PDR is mainly being driven by NNRTIs, and this has been 
consistent with other regional findings from Uganda (7.5%) [74], Botswana (8%) [75] and 
Angola (14%) [76]. A continual increase in levels of PDR could have several consequences on 
HIV-related deaths, new infections and on ART program costs, with predicted costs of up to $6.5 
billion that could be incurred in sub-Saharan Africa alone, between 2016 and 2030, if no changes 
are made in ART programs once PDR levels reach ≥10% [77].  
 
PDR mutations at low frequencies could also pose a risk of ART failure with a few studies from 
high-income counties showing that pre-treatment NNRTI-DRMVs have an impact on NNRTI-
based ART outcomes [71,78–81]. On the other hand, the CASTLE study done across 5 
continents, showed that transmitted DRMVs had no significant effect on PI-based regimens (i.e. 
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atazanavir/ritonavir or LPV/r), even in patients with NNRTI-DRMVs [81]. Such conflicting 
findings warrant the need for further research into DRMVs, and considering most studies on 
DRMVs have been done in participants predominantly infected with HIV-1 subtype B virus (or 
non-C subtypes), understanding the role of DRMVs on ART in subtype C-dominant populations 
is required. In addition, understanding these dynamics in patients with HIV and tuberculosis (TB) 
co-infection (HIV/TB) is of great importance since HIV infected individuals are 10 times more 
likely to develop TB, with it being the leading cause of death in people living with HIV [82]. 
Ultimately, the goal will be to understand how NGS results can be interpreted for use in routine 
clinical practice, to inform treatment decisions that help improve the quality of patient care. 
 
1.6 Main objective 
To assess levels of PDR in HIV hyper-endemic settings and South Africa in general, and to 
understand the impact of PDR on treatment response, including DRMVs.  
 
1.6.1. Specific objectives 
1. To describe levels of PDR in two-population based studies in HIV hyper-endemic 
settings, in northern and central KZN 
2. To describe the trends in the levels of PDR and the impact of PDR on treatment response, 
in South Africa 
3. To describe the impact of pretreatment DRMVs on ART in individuals receiving 
concurrent HIV/TB treatment 
 
1.7 Research methods 
1.7.1 Study area 
1.7.1.1 Africa Health Research Institute longitudinal HIV surveillance programme 
This study used sequence data from both longitudinal and cross-sectional studies. It involved 
analysis of sequence data from two HIV hyper-endemic settings in KZN and across South Africa. 
One of the studies from which we harnessed sequence data to assess levels of PDR is a 
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longitudinal HIV surveillance programme in the uMkhanyakude district in KZN. The longitudinal 
household HIV surveillance programme was started in January 2003, following setup of a 
demographic surveillance system in 2000, by the Africa Health Research Institute (AHRI) [83]. 
In summary, the demographic surveillance area is in the southern part of the Umkhanyakude 
district in northern KZN. Its is approximately 440 km2 in size and home to about 11 000 
households and about 90 000 people [84]. The study population includes all household members 
in the area. Through the household survey, demographic and clinical information is collected 
from all registered households every year in a two-phased approach. Firstly, a household survey 
is administered every four months to a senior household member to report on all resident and 
non-resident individuals in the household. Secondly, each year trained workers collect 
information from individuals 15 years and older through interviews, and HIV testing is offered to 
each individual [85]. A dried blood spot specimen is collected for HIV related tests, such as viral 
load and drug resistance testing.  
 
From 2003 to 2007 the eligibility criteria for testing as an adult in the surveillance programme 
was 15 – 54 years for men and 15 – 49 years for women. After 2007, all individuals >15 years of 
age who reside in the area are eligible for HIV testing. There are six primary health care clinics in 
the surveillance area where ART can be accessed for free [85,86]. Based on all HIV positive 
adults, ART coverage was estimated at 30.7% (29.3 – 32.1) and the HIV prevalence in the area 
was as high as 29.0% (27.9–30.1), in 2011 [87]. The HIV incidence rates have been recorded as 
6.6 per 100 person-years in women aged 24 years and at 4.1 per 100 person-years in men aged 29 
years [88]. Details of the AHRI health surveillance area have been published previously [83,85–
88]. Figure 9 shows a map of the AHRI surveillance area. 
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Figure 9 Geographic location of the AHRI study area in uMkhanyakude district, KZN (Namosha E 
et al., PLOS One, 2013) 
 
On the left is a map of South Africa, showing the location of the uMkhanyakude district 
(shaded) in KZN province. On the right is a map showing the AHRI health surveillance area in the 
uMkhanyakude district. 
 
1.7.1.2 The HIV Incidence Provincial Surveillance System  
The HIV Incidence Provincial Surveillance System (HIPSS) is coordinated by the Epicentre AIDS 
Risk Management, the Centre for the AIDS Programme of Research in South Africa (CAPRISA), 
and the United States Centers for Disease Control and Prevention. It is a HIV household survey that 
is conducted in two neighboring sub-districts of the uMgungundlovu district in central KZN [89–
91]. In summary, HIPSS is a HIV cross-sectional survey of randomly selected individuals between 
the ages of 15–49 years living in the Vulindlela and Greater Edendale sub-districts of the 
uMgungundlovu district. The survey has broad objectives that aim at assessing the effectiveness of 
programmatic HIV intervention efforts in a non-trial setting. This includes (but is not limited to) 
estimating the proportion of people on ART in the surveillance area, the prevalence of HIV, 
measuring temporal trends of HIV incidence, community viral loads, the levels of CD4 counts in 
largest peri-urban area within KZN and is the main eco-
nomic hub within the uMgungundlovu district. It is linked
to Vulindlela by a dual carriage way known as the Edendale
Corridor. This route serves as the connection between
various outlying rural areas to the north of Pietermaritz-
burg. Much of the Greater Edendale Area is developed with
both formal and informal housing, supported in some areas
by ancillary land uses and facilities.
Fig. 1 Location of Greater Edendale and Vulindlela study area in KwaZulu-Natal, South Africa




HIV infected individuals, and the proportion that are treatment naive with detectable and 
undetectable viral loads. It also includes estimating the prevalence of pulmonary TB, sexually 
transmitted infections (STIs), hepatitis B and C infections, prevalence of ART resistance, and to 
identify HIV transmission networks and risk factors for HIV incidence at the individual, household 
and community levels [91].  
 
The study area represents peri-urban, rural traditional settlements, farmlands and informal 
settlements in the district. Vulindlela is largely a rural community dominated by Zulu speaking 
people, with a population of around 150,000 people in 2015 and the Greater Edendale area is the 
second largest peri-urban area in KZN, with a population of approximately 210,000 people in 2015, 
and has been the main economic hub of the district [91]. The study area has 16 primary health care 
facilities supported by three district hospitals, and 60 community-based organizations that provide 
HIV prevention and home-based care services. The are approximately 95,000 households in which 
approximately 368,000 people reside, 176,000 (48%) being males and 192,000 (52%) females, with 
the majority (50%) of people being those between the ages of 15–49 years [91].  
 
The HIPPS study used a two-stage cluster-based sampling method of enumeration areas to 
randomly select households. Households were then identified using geographic coordinates from a 
global positioning system receiver [91]. Only one individual per household was enrolled and if the 
individual refused to participate in the survey, the next randomly selected individual was enrolled in 
the study, and subsequent refusal was followed by replacing the household [91]. During the study 
the head of household was identified and data of the age, gender, and basic socio-demographic 
profile of all usual household members was recorded. The individual who meets the eligibility 
criteria, aged between 15 - 49 years, was enrolled and biological specimens (i.e. blood, sputum, 
urine (in males) and vaginal swabs (in females)) were collected for testing [91]. Longitudinal 
follow-ups were done in all enrolled HIV negative individuals aged between 15 - 35 years. Details 




Figure 10 Geographic location of the HIPSS study area in uMgungundlovu district, KZN 
(Kharsany et al. BMC Public Health, 2015)  
On the left is a map of South Africa, showing the location of the uMgungundlovu district 
(shaded) in KZN province. On the right is a map showing the HIPSS study area in the 
uMgungundlovu district. 
 
Levels of PDR were analyzed using these two cohorts (AHRI and HIPPS), as well as by combining 
the sequences with national PDR data. 
 
1.7.1.3 Starting ART at three points in tuberculosis treatment (SAPIT trial) 
Starting antiretroviral therapy at three points in tuberculosis treatment (known as the SAPiT trial) 
was an open-label, randomized, controlled trial in Durban, South Africa, conducted by CAPRISA 
between June 2005 and July 2008, that aimed at assessing the optimal timing for ART initiation in 
patients with HIV/TB co-infection. In summary, the study was conducted at the eThekwini Clinical 
Research site (ECRS) which is next to the Prince Cyril Zulu Communicable Disease Centre; one of 
the largest TB facilities for outpatients in South Africa [92,93]. The ECRS is located in Durban's 
central business district close to commuters from local townships and outlying areas, and it has a 
HIV/TB treatment clinic and a STI prevention clinic, which offer free diagnosis and treatment for 
TB and STIs [93]. Patients with confirmed HIV/TB co-infection were recruited upon consent and 
they were randomly assigned to one of three study arms in a 1:1:1 ratio [92]. In the first arm, 
patients were initiated on ART within a month of initiating TB treatment and were known as the 
uMgungundlovu
District
largest peri-urban area within KZN and is the main eco-
nomic hub within the uMgungundlovu district. It is linked
to Vulindlela by a dual carriage way known as the Edendale
Corridor. This route serves as the connection between
various outlying rural areas to the north of Pietermaritz-
burg. Much of the Greater Edendale Area is developed with
both formal and informal housing, supported in some areas
by ancillary land uses and facilities.
Fig. 1 Location of Greater Edendale and Vulindlela study area in KwaZulu-Natal, South Africa
Kharsany et al. BMC Public Health  (2015) 15:1149 Page 4 of 11
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integrated-therapy group. In the second arm, ART was initiated within a month of completing the 
intensive TB treatment phase, and these were the late integrated-therapy group. The third arm had 
patients who initiated ART within a month of completing the continuation phase of TB treatment, 
and was called the sequential-therapy group [92].   
 
During the recruitment period (2005-2008) consenting TB patients ≥18 years of age with confirmed 
HIV infection (using two rapid HIV tests) were enrolled. All patients received adherence 
counseling, prophylaxis against HIV-related opportunistic infections, and the same once-daily ART 
regimen of didanosine (ddI) + 3TC + EFV [92,94]. The primary end point was death from any 
cause and secondary end points were treatment discontinuation due to adverse drug reactions, poor 
HIV suppression and TB outcomes, and the occurrence of the immune reconstitution inflammatory 
syndrome [92]. Results of the SAPiT trial helped determine the optimal time for initiating ART in 
HIV/TB co-infected patients, and the findings resulted in changes in treatment policies by the WHO 
and South African government. A continuation study of the SAPiT trial, known as “TB Recurrence 
upon Treatment with HAART” (TRuTH), was done to assess if TB recurrence in HIV/TB treated 
patients is due to relapse or re-infection. Each case of TB recurrence on ART was investigated to 
assess whether the infecting Mycobacterium tuberculosis is similar to the one from the previous 
infection and whether immune responses differ when there is relapse and re-infection [93]. Further 
details of the SAPiT study have been published previously [92,94].  Samples collected from this 
cohort were used to assess the impact of DRMVs on ART.  
 
1.7.2 Ethical approval 
Ethical approval for the AHRI and HIPSS studies were obtained from the Biomedical Research 
Ethics Committee of the University of KwaZulu-Natal (UKZN) (reference numbers BF233/09 and 
BF269/13) the KZN Provincial Department of Health (HRKM 08/14) and the Centre for Global 
Health, CDC. Ethical approval for the SAPiT (reference number: E107/05) and TRuTH (reference 
number: BF051/09) studies, were obtained from the Biomedical Research Ethics Committee of the 
UKZN. Ethical approval to investigate the impact of DRMVs on ART (reference number: 
BF340/17) was obtained from the Biomedical Research Ethics Committee of the UKZN (Appendix 
1). Participants gave informed consent for sample storage and sample use for future studies.  
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1.8 Thesis outline 
This thesis comprises a background, literature review and justification in chapter 1, manuscripts 
in chapters 2 to 5 and a synthesis consolidating the findings of the thesis in chapter 6. Manuscript 
formats and referencing styles used in chapters 2 to 5 are according to specific journal 
requirements, and published papers have been presented in their current publication format. 
 
Chapter 1: Introduction, literature review and justification 
This chapter introduces the work that was conducted and provides an overall literature review on 
HIV drug resistance.  
 
Chapter 2: Manuscript: “Primary HIV-1 drug-resistant minority variants” 
This chapter reviewed the topic of pretreatment DRMVs, the challenges in NGS implementation, 
and the knowledge gaps in HIV resistance. 
 
Chapter 3: Manuscript: “Moderate to high levels of pre-treatment HIV drug resistance in 
KwaZulu-Natal Province, South Africa” 
This chapter is based on a study that was done to assess PDR in adult ART naïve patients from 
two population-based studies, in HIV hyper-endemic, in KZN.  
 
Chapter 4: Manuscript: “Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-
naive adults in South Africa, 2000 – 2016: a pooled sequence analysis.” 
This chapter is based on a meta-analysis study that was done to assess trends of PDR in adult 
ART naïve patients across South Africa, before and after scale-up of ART in 2010. 
 
Chapter 5: Manuscript: “Impact of HIV pre-treatment drug resistant minority variants on 
antiretroviral therapy in HIV/TB co-infected patients.” 
This chapter is based on a study that was done to assess if standard genotypic resistance testing 
underestimates pretreatment resistance and, if so, the impact that DRMVs have on clinical 
outcomes. 
 
Chapter 6: Synthesis of the thesis 
The final chapter presents an overall synthesis of the thesis, consolidating the key findings of data 
presented as manuscripts in chapters 3 to 5, as well as recommendations for policy, and for future 
research, based on research findings. 
 22 
1.9 References 
1.  Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, et al. Origin of HIV-1 
in the chimpanzee Pan troglodytes troglodytes. Nature. 1999;397: 436–441.  
2.  Sharp PM, Hahn BH. Origins of HIV and the AIDS Pandemic. Cold Spring Harb Perspect 
Med. 2011;1: a006841.  
3.  Daw MA, El-Bouzedi A, Ahmed MO, Dau AA. Molecular and epidemiological 
characterization of HIV-1 subtypes among Libyan patients. BMC Res Notes. 2017;10: 170.  
4.  Abecasis AB, Vandamme A-M, Lemey P. Quantifying differences in the tempo of human 
immunodeficiency virus type 1 Subtype evolution. J Virol. 2009;83: 12917–12924.  
5.  Tongo M, Dorfman JR, Martin DP. High degree of HIV-1 group M (HIV-1M) genetic 
diversity within circulating recombinant forms: insight into the early events of HIV-1M 
evolution. J Virol. 2016;90: 2221 LP-2229.  
6.  Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 
subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J 
Virol. 2007;81: 10209–19.  
7.  UNAIDS. Global HIV & AIDS statistics — 2018 fact sheet. 2018; Available: 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf 
8.  UNAIDS. UNAIDS Data. 2018; Available: 
http://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf 
9.  CIA world factbook - HIV/AIDS adult prevalence rate. 2016; Available: 
https://www.cia.gov/library/publications/the-world-factbook/rankorder/2155rank.html 
10.  WHO. Antiretroviral therapy coverage data and estimates by country. 2016; Available: 
http://apps.who.int/gho/data/node.main.626?lang=en 
11.  UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. 2014; 1–
40. Available: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf 
12.  UNAIDS. Fast-track: Ending the AIDS epidemic by 2030. 2014; Available: 
www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf 
13.  Lima VD, St-Jean M, Rozada I, Shoveller JA, Nosyk B, Hogg RS, et al. Progress towards 
the United Nations 90-90-90 and 95-95-95 targets: the experience in British Columbia, 
Canada. J Int AIDS Soc. 2017;20: e25011.  
14.  SABSSM V. HIV impact assessment summary: The fifth South African national HIV 
prevalence, incidence, behaviour and communication survey, 2017. 2018;  
 23 
15.  KwaZulu-Natal Provincial Government. Province of KwaZulu-Natal; Socio-Economic 
Review and Outlook 2017/2018. 2018; Available: 
http://www.kzntreasury.gov.za/ResourceCenter/Documents  Fiscal Resource 
Management/SERO_Final_28 Feb 2017.pdf 
16.  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. 
Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375: 
830–839.  
17.  AJ R, Cambiano V, Bruun T, Al E. Sexual activity without condoms and risk of HIV 
transmission in serodifferent couples when the hiv-positive partner is using suppressive 
antiretroviral therapy. JAMA. 2016;316: 171–181.  
18.  Katz IT, Maughan-Brown B. Improved life expectancy of people living with HIV: Who is 
left behind? Lancet HIV. 2018;4: e324-326.  
19.  Arts EJ, Hazuda DJ. HIV-1 Antiretroviral Drug Therapy. Cold Spring Harb Perspect Med. 
2012;2: a007161.  
20.  WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing 
HIV infection: Recommendations for a public health approach; second edition. 2016; 
Available: http://apps.who.int/iris/bitstream/10665/208825/1/ 9789241549684_ 
eng.pdf?ua=1 
21.  Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of 
antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373: 795–
807.  
22.  TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le 
Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N 
Engl J Med. 2015;373: 808–822.  
23.  South Africa National Department of Health. Implementation of the universal tests and treat 
strategy for HIV positive patients and differentiated care for stable patients. 2016; Available: 
http://www.sahivsoc.org/Files/22 8 16 Circular UTT Decongestion CCMT Directorate 
(2).pdf 
24.  Govender K. South Africa’s adoption of the World Health Organization’s “test and treat” 
guidelines: Are we too ambitious? SAJM. 2016;106: 952.  




26.  Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, et al. Adult 
antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017;18: 776.  
27.  Gouws E, Cuchi P. Focusing the HIV response through estimating the major modes of HIV 
transmission: a multi-country analysis. Sex Transm Infect. 2012;88: i76-85.  
28.  Bulterys M, Fowler MG, Van Rompay KK, Kourtis AP. Prevention of mother-to-child 
transmission of HIV-1 through breast-feeding: past, present, and future. J Infect Dis. 
2004;189: 2149–2153.  
29.  Mukhopadhyay P, Kumar V, Rathi M, Kohli HS, Jha V, Sakhuja V. Transmission of human 
immunodeficiency virus infection by renal transplantation. Indian J Nephrol. India; 2012;22: 
133–135.  
30.  UNAIDS. Undetectable = Untransmittable: Public health and HIV viral load suppression. 
2018; Available: http://www.unaids.org/sites/default/files/media_asset/undetectable-
untransmittable_en.pdf 
31.  Simelela N, Venter W. A brief history of South Africa’s response to AIDS. S Afr Med J. 
2014;104: 249–51.  
32.  Plazy M, Dabis F, Naidu K, Orne-Gliemann J, Barnighausen T, Dray-Spira R. Change of 
treatment guidelines and evolution of ART initiation in rural South Africa: data of a large 
HIV care and treatment programme. BMC Infect Dis. London; 2015;15: 452.  
33.  National Department of Health (South Africa). National consolidated guidelines for 
prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in 
children, adolescents and adults. 2015; Available: https://aidsfree.usaid.gov/ 
sites/default/files/tx_south-africa_pmtct_2015.pdf 
34.  World Health Organization. Consolidated guideline on sexual and reproductive health and 
rights of women living with HIV. 2017.  
35.  Rossouw T, Lessells R, de Oliveira T. HIV & TB drug resistance & clinical management 
case book. South African Medical Research Council Press; 2013; Available: 
http://www.bioafrica.net/manuscripts/HIVTBDrugResistanceCaseBookSmallPDF.pdf 
36.  Masikini P, Mpondo BCT. HIV drug resistance mutations following poor adherence in HIV-
infected patient: a case report. Clin Case Reports. 2015;3: 353–356.  
37.  Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene 
expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138: 
103–141.  
38.  van de Vijver D, Boucher C. The risk of HIV drug resistance following implementation of 
 25 
pre-exposure prophylaxis. Curr Opin Infect Dis. 2010;23: 621–7.  
39.  Sultan B, Benn P, Waters L. Current perspectives in HIV post-exposure prophylaxis. HIV 
AIDS (Auckl). 2014;6: 147–158.  
40.  Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, et al. Persistence of 
nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of 
maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci. 2006;103: 7094–7099.  
41.  World Health Organization. Guidelines on the public health response to pretreatment HIV 
drug resistance. 2017; Available: 
http://apps.who.int/iris/bitstream/10665/255880/1/9789241550055-eng.pdf 
42.  Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 
drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-
income and middle-income countries: a systematic review and meta-regression analysis. 
Lancet Infect Dis. 2018;18: 346–355.  
43.  Hu W-S, Hughes SH. HIV-1 reverse transcription. Cold Spring Harb Perspect Med. 2012;2: 
a006882.  
44.  Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype 
diversity. N Engl J Med. 2008;359: 1965–1966.  
45.  Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, et al. The effect of transmitted 
HIV-1 drug resistance on pre-therapy viral load. AIDS. 2010;24: 1917–1922.  
46.  Poon AFY, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, et al. Transmitted 
drug resistance in the CFAR network of integrated clinical systems cohort: Prevalence and 
effects on pre-therapy CD4 and viral load. PLoS One. 2011;6: e21189.  
47.  Ávila-Ríos S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D, 
Quiroz-Morales VS, et al. Pretreatment HIV-drug resistance in Mexico and its impact on the 
effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO 
survey. Lancet HIV. 2018;3: e579–e591.  
48.  Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, et al. 
Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with 
virologic failure: Results from the multinational PEARLS (ACTG A5175) clinical trial. Clin 
Infect Dis An Off Publ Infect Dis Soc Am. 2015;60: 1541–1549.  
49.  Tang MW, Shafer RW. HIV-1 antiretroviral resistance: Scientific principles and clinical 
applications. Drugs. 2012;72: e1–e25.  
50.  Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for 
 26 
surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral 
treatment. Antivir Ther. 2008;13: 25–36.  
51.  World Health Organization. Guidelines for surveillance of HIV drug resistance. 2003; 
Available: http://www.who.int/3by5/publications/guidelines/en/resisguide.pdf 
52.  World Health Organization. The HIV drug resistance report 2017. Geneva; 2017; Available: 
http://apps.who.int/iris/bitstream/10665/255896/1/97892415128 31-eng.pdf 
53.  World Health Organization. Global action plan on HIV drug resistance 2017–2021. Geneva; 
2017; Available: http://apps.who.int/iris/bitstream/10665/255883/1/97892415128 48-eng.pdf 
54.  Manasa J, Katzenstein D, Cassol S, Newell M-L, de Oliveira T. Primary drug resistance in 
South Africa: Data from 10 years of surveys. AIDS Res Hum Retroviruses. 2012;28: 558–
565.  
55.  Manasa J, Lessells RJ, Skingsley A, Naidu KK, Newell M-L, McGrath N, et al. High-levels 
of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural 
HIV treatment programme in KwaZulu-Natal, South Africa. PLoS One. 2013;8: e72152.  
56.  Ndembi N. Adherence to Antiretroviral Therapy, Retention in Care and HIV Drug 
Resistance in Nigeria. Curr HIV Res. 2015;13: 260–261.  
57.  Herbeck JT, Mittler JE, Gottlieb GS, Goodreau SM, Murphy JT, Cori A, et al. Evolution of 
HIV virulence in response to widespread scale up of antiretroviral therapy: a modeling 
study. Virus Evol. 2016;2: vew028-vew028.  
58.  García-Lerma JG, Heneine W. Rapid biochemical assays for phenotypic drug resistance 
testing of HIV-1. J Antimicrob Chemother. 2002;50: 771–774.  
59.  Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. 
Clin Infect Dis. 2006;42: 1608–1618.  
60.  Wensing A, Calvez V, Günthard H, Johnson V, Paredes R, Pillay D, et al. 2017 Update of 
the drug resistance mutations in HIV-1. Top Antivir Med. 2017;24: 132–133.  
61.  Sen S, Tripath S, Paranjape R. Antiretroviral drug resistance testing. J Postgr Med. 2006;52.  
62.  Li JZ, Kuritzkes DR. Clinical implications of HIV-1 minority variants. CID. 2013;56: 1667–
1674.  
63.  Chimukangara B, Samuel R, Naidoo K, de Oliveira T. Primary HIV-1 drug-resistant 
minority variants. AIDS Rev. 2017;19: 89–96.  
64.  Panpradist N, Beck IA, Chung MH, Kiarie JN, Frenkel LM, Lutz BR. Simplified paper 
format for detecting HIV drug resistance in clinical specimens by oligonucleotide ligation. 
PLoS One. 2016;11: e0145962.  
 27 
65.  MacLeod I, Rowley C, M E. Pan degenerate amplification and adaptation for highly 
sensitive detection of ARV drug resistance. Conference on Retroviruses and Opportunistic 
Infections (CROI 2014); Boston, MA, USA; March 3–6 : abstr 606. 2014;  
66.  Clutter DS, Sánchez PR, Rhee S-Y, Shafer RW. Genetic variability of HIV-1 for drug 
resistance assay development. Viruses. 2016;8: 48.  
67.  Rhee S-Y, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, et al. HIV-1 drug resistance 
mutations: Potential applications for point-of-care genotypic resistance testing. PLoS One. 
2016;10: e0145772.  
68.  van Zyl GU, Frenkel LM, Chung MH, Preiser W, Mellors JW, Nachega JB. Emerging 
antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are 
needed to provide resistance testing for individual and public health benefits. AIDS. 
2014;28: 2643–2648.  
69.  Drain PK, Rousseau C. Point-of-care diagnostics: extending the laboratory network to reach 
the last mile. Curr Opin HIV AIDS. 2017;12: 175–181.  
70.  Gupta S, Lataillade M, Kyriakides TC, Chiarella J, St John EP, Webb S, et al. Low-
frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in 
antiretroviral-naïve subjects. Viruses. 2014;6: 3428–37.  
71.  Li JZ, Paredes R, Ribaudo H, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Minority HIV-1 
drug resistance mutations and the risk of NNRTI-based antiretroviral treatment failure: A 
systematic review and pooled analysis. JAMA. 2011;305: 1327–1335.  
72.  Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, et al. 
Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance detected in the first 
South African National survey. PLoS One. 2016;11: e0166305.  
73.  van Zyl GU, Grobbelaar CJ, Claassen M, Bock P, Preiser W. Moderate levels of pre-therapy 
drug resistance (PDR) in a generalised epidemic: time for better first-line ART? AIDS. 
2017;13: 2387–2391.  
74.  Kityo C, Sigaloff KCE, Boender TS, Kaudha E, Kayiwa J, Musiime V, et al. HIV drug 
resistance among children initiating first-line antiretroviral treatment in Uganda. AIDS Res 
Hum Retroviruses. 2016;32: 628–635.  
75.  Rowley CF, MacLeod IJ, Maruapula D, Lekoko B, Gaseitsiwe S, Mine M, et al. Sharp 
increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana 
demonstrates the need for routine surveillance. J Antimicrob Chemother. 2016;71: 1361–
1366.  
 28 
76.  Afonso JM, Bello G, Guimarães ML, Sojka M, Morgado MG. HIV-1 genetic diversity and 
transmitted drug resistance mutations among patients from the North, Central and South 
regions of Angola. PLoS One. 2012;7: e42996.  
77.  Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, et al. Impact of HIV 
drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral 
therapy program costs in sub-Saharan Africa. J Infect Dis. 2017;215: 1362–1365.  
78.  Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, et 
al. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-
based ART: a multicohort European case–control study using centralized ultrasensitive 454 
pyrosequencing. J Antimicrob Chemother. 2015;70: 930–940.  
79.  Cunningham E, Chan Y-T, Aghaizu A, Bibby DF, Murphy G, Tosswill J, et al. Enhanced 
surveillance of HIV-1 drug resistance in recently infected MSM in the UK. J Antimicrob 
Chemother. 2017;72: 227–234.  
80.  Johnson JA, Li J-F, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug 
resistance mutations are present in antiretroviral treatment–naïve populations and associate 
with reduced treatment efficacy. PLoS Med. 2008;5: e158.  
81.  Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, et al. Prevalence and 
clinical significance of HIV drug resistance mutations by ultra-deep sequencing in 
antiretroviral-naïve subjects in the CASTLE study. PLoS One. 2010;5: e10952.  
82.  Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-
infection. Nat Rev Microbiol. 2017;16: 80.  
83.  Tanser F, Hosegood V, Bärnighausen T, Herbst K, Nyirenda M, Muhwava W, et al. Cohort 
profile: Africa Centre Demographic Information System (ACDIS) and population-based 
HIV survey. Int J Epidemiol. 2008;37: 956–962.  
84.  Vandormael A, Bärnighausen T, Herbeck J, Tomita A, Phillips A, Pillay D, et al. 
Longitudinal trends in the prevalence of detectable HIV viremia: Population-based evidence 
from rural KwaZulu-Natal, South Africa. Clin Infect Dis. 2018;66: 1254–1260.  
85.  Maheu-Giroux M, Tanser F, Boily M-C, Pillay D, Joseph SA, Bärnighausen T. 
Determinants of time from HIV infection to linkage-to-care in rural KwaZulu-Natal, South 
Africa. AIDS. 2017;31: 1017–1024.  
86.  Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H, et al. Cohort 
profile: Hlabisa HIV treatment and care programme. Int J Epidemiol. 2011;40: 318–326.  
87.  Zaidi J, Grapsa E, Tanser F, Newell M-L, Bärnighausen T. Dramatic increases in HIV 
 29 
prevalence after scale-up of antiretroviral treatment: a longitudinal population-based HIV 
surveillance study in rural Kwazulu-Natal. AIDS. 2013;27: 2301–2305.  
88.  Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High coverage of ART 
associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. 
Science. 2013;339: 966–971.  
89.  de Oliveira T, Kharsany ABM, Gräf T, Cawood C, Khanyile D, Grobler A, et al. 
Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a 
community-wide phylogenetic study. Lancet HIV. 2017;4: e41-50.  
90.  Grobler A, Cawood C, Khanyile D, Puren A, Kharsany ABM. Progress of UNAIDS 90-90-
90 targets in a district in KwaZulu-Natal, South Africa, with high HIV burden, in the HIPSS 
study: a household-based complex multilevel community survey. Lancet HIV. 2017;4: e505-
513.  
91.  Kharsany ABM, Cawood C, Khanyile D, Grobler A, Mckinnon LR, Samsunder N, et al. 
Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a 
longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, 
KwaZulu-Natal, South Africa. BMC Public Health. 2015;15: 1149.  
92.  Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of 
initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697–
706.  
93.  CAPRISA. HIV and TB treatment. Available: https://www.caprisa.org/Pages/HIV-and-TB-
Treatment 
94.  Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in 
multi-drug resistant tuberculosis patients receiving integrated TB and ART in the SAPiT 
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The manuscript in chapter 2 gave an overview of PDR, challenges with NGS implementation, and 
the current knowledge gaps that exist in the filed of HIVDR, in relation to NGS. It also 
emphasizes on the importance of understanding the impact of DRMVs and adequately estimating 
the prevalence and patterns of PDR in settings where genotypic testing assays are not feasible at 
ART initiation. This motivated the following chapters; assessing levels of PDR as detected by 
Sanger sequencing (chapter 3 and 4), and the impact of DRMVs on ART (chapter 5). The 
following chapter presents a study that was conducted to assess levels of PDR in adult ART naïve 
patients in two HIV hyper-endemic settings in KZN, South Africa. The manuscript 

























CHAPTER 3: MODERATE TO HIGH LEVELS OF PRE-TREATMENT HIV DRUG 
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   T215DEV 0.4 0 0.1 0 0.1 
   T215Y 0.4 0 0 0 0.1 
   K219ENR 0.8 0.6 0.3 0.2 0.4 
Overall NRTI 
resistance  
4.7 3.4 3.1 2.4 3.2 
PI Mutationsa n=254 n=356 n=736 n=495 n=1841 
   L24I 0 0 0 0.2 0.1 
   M46IL 0.4 0.6 0.7 2.0       1.0 
   F53Y 0 0 0 0.2 0.1 
   I54V 0.4 0.3 0 0 0.1 
   L76V 0.4 0.3 0 0 0.1 
   V82A 0.4 0.3 0 0 0.1 
   I85V 0 0.3 0 0.4 0.2 
   L90M 0.8 0 0 0 0.1 
Overall PI 
resistance  
0.8 0.8 0.7 2.6 1.2 
AHRI, Africa Health Research Institute; HIPSS, HIV Incidence Provincial 
Surveillance System; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, 
nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor 
All figures are percentages; figures in bold and underlined are levels of resistance 
≥5% 
The following surveillance drug resistance mutations were not detected in either 
study and are therefore not listed: L23I, D30N, V32I, I47VA, G48VM, I50LV, 
G73STCA, N83D, I84VAC, N88DS, T69ins, V75MTAS, F77L, F116Y, Q151M, 
V179F 



















The manuscript in chapter 3 showed important results that suggested HIV PDR has increased in 
KZN, with NNRTI-PDR exceeding 10% in sequences collected in 2014 in the HIPSS study. This 
provided the first evidence of NNRTI-PDR ≥10% in South Africa. Considering that the WHO 
guidelines now recommend switching to DTG-based ART when NNRTI-PDR levels reach levels 
of ≥10%, this study was done at a timely moment, supporting the transition to DTG-based first-
line ART. Further to the findings of high levels of NNRTI-PDR in KZN, we conducted a meta-
analysis of sequence data from all pre-ART drug resistance studies in South Africa. This included 
all studies on adult ART naïve individuals, conducted between January 2000 and September 
2016, including sequences from the two population-based studies described in chapter 3. The 
following chapter presents a meta-analysis that was done on assessing the trends of PDR in South 






















CHAPTER 4: TRENDS IN PRETREATMENT HIV-1 DRUG RESISTANCE IN 
ANTIRETROVIRAL THERAPY-NAIVE ADULTS IN SOUTH AFRICA, 2000 – 2016: 
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Summary (244 words) 
Background South Africa has the largest public antiretroviral therapy (ART) programme in the 
world. We assessed temporal trends in pretreatment HIV-1 drug resistance (PDR) in ART-naïve 
adults from South Africa.  
 
Methods We included datasets from studies conducted between 2000 and 2016, with HIV-1 pol 
sequences from more than ten ART-naïve adults. We analysed sequences for the presence of 101 
surveillance drug resistance mutations (SDRMs). We pooled sequences by sampling year and 
performed a sequence-level analysis using a generalized linear mixed model, including the dataset 
as a random effect.  
 
Findings We identified 38 datasets, and retrieved 6880 HIV-1 pol sequences for analysis. The 
pooled annual prevalence of PDR remained below 5% until 2009, then increased to a peak of 
11·9% (95% CI 9·2-15·0) in 2015. The pooled annual prevalence of non-nucleoside reverse-
transcriptase inhibitor (NNRTI) PDR remained below 5% until 2011, then increased to 10·0% (95% 
CI 8·4-11·8) by 2014. Between 2000 and 2016, there was a 1·18-fold (95% CI 1·13-1·23) annual 
increase in NNRTI PDR (p<0·001), and a 1·10-fold (95% CI 1·05 – 1·16) annual increase in 
nucleoside reverse-transcriptase inhibitor PDR (p=0·001).  
 
Interpretation Increasing PDR in South Africa presents a threat to the efforts to end the HIV/AIDS 
epidemic. These findings support the recent decision to modify the standard first-line ART regimen, 
but also highlight the need for broader public health action to prevent the further emergence and 
transmission of drug-resistant HIV. 
 
Source of funding: This work was supported by a flagship grant from the South African Medical 
Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI).  
 
Disclaimer: The contents of this publication are solely the responsibility of the authors and do not 
necessarily represent the official views of CDC. 
 




Research in context  
Evidence before this study  
We searched PubMed for systematic reviews and meta-analyses of pretreatment or transmitted HIV 
drug resistance in South Africa. We used the search terms HIV AND South Africa AND drug 
resistance AND (systematic review OR meta-analysis). We found two meta-analyses exploring 
regional prevalence of pretreatment or transmitted HIV drug resistance, where data from South 
Africa were combined with data from other countries in a regional analysis (southern Africa or sub-
Saharan Africa). We found a meta-analysis of pretreatment HIV drug resistance in children younger 
than 12 years, which included data from South Africa. We also found a systematic review from our 
own group which analysed transmitted drug resistance up to 2010. We did not identify any studies 
that focused on South Africa and incorporated sequences collected since 2010, when scale-up of 
antiretroviral therapy accelerated.     
 
Added value of this study  
In this pooled analysis of 6880 HIV-1 sequences from 38 datasets, we provide up-to-date estimates 
of the prevalence of pretreatment HIV drug resistance (PDR) in South Africa. We present evidence 
of increasing PDR, particularly since the acceleration of ART scale-up in 2010. We demonstrate 
that the increase is largely driven by non-nucleoside reverse-transcriptase inhibitor (NNRTI) PDR, 
but that levels of nucleoside reverse-transcriptase inhibitor (NRTI) PDR are also rising. In 
particular, we note a concerning increase in the prevalence of tenofovir resistance-associated 
mutations (TRAMs), which could have important implications for current treatment and prevention 
strategies.  
 
Implications of all the available evidence  
Our findings provide clear evidence that PDR in South Africa has reached the threshold at which 
the World Health Organization recommends urgent public health action (NNRTI PDR >10%). 
Whilst our data provide support for the decision to move to a new dolutegravir-based first-line 
regimen, they also highlight the broader need to improve quality of HIV treatment and prevention if 






The roll-out of antiretroviral therapy (ART) has been a major breakthrough in the global response to 
HIV, helping to reduce HIV-related deaths by 48% between 2005 and 2016, and new HIV 
infections by 11% between 2010 and 2016.1 Despite these impressive public health gains, 
substantial expansion of access to ART will be required to achieve the target of ending the HIV 
epidemic by 2030. The emergence and transmission of HIV drug resistance (HIVDR) poses a threat 
to the successful treatment and prevention of HIV, and there is now strong evidence that levels of 
HIVDR are increasing substantially in southern Africa, the region that faces the greatest challenges 
to ending the HIV epidemic. 
 
Pretreatment HIV drug resistance (PDR) is drug resistance in a person initiating or re-initiating 
ART (i.e. with or without prior ART exposure).2,3 PDR can arise in one of three ways: transmission 
of drug-resistant HIV from a person with acquired drug resistance (ADR); transmission of primary 
drug-resistant HIV from another ART-naïve person; or ADR resulting from prior exposure to 
antiretroviral drugs for treatment or prevention. The presence of PDR is associated with poorer 
virological outcomes on first-line ART.4,5  
 
South Africa, with over seven million people living with HIV (PLHIV) in 2016, accounts for almost 
one in five PLHIV globally.1 The country has the largest public ART program in the world, with 
more than four million people on ART by early 2018.6  In the first few years of ART rollout, the 
levels of PDR were low (<5%).7 More recent studies, conducted since the accelerated expansion of 
ART coverage in 2010, have suggested higher levels of PDR8,9.  
 
Given this evidence of rising levels of PDR in the country and the wider region, and the continued 
expansion of ART for treatment and prevention, we performed a pooled analysis of HIV sequence 
data from South Africa, firstly to determine the annual trends in PDR and secondly to explore in 
detail the patterns of observed drug resistance mutations.  
 
Methods 
Search strategy and selection criteria 
This study was a systematic review and pooled analysis aimed at determining trends in PDR 
amongst ART-naïve adults in South Africa. We conducted and reported this in line with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 
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(checklist included in appendix, p1).10 To identify relevant studies we first searched for published 
articles in MEDLINE using the OvidSP interface on 12 September 2017 (appendix, p 3). We then 
scanned the reference lists of all articles selected for inclusion and conducted forward citation 
searches using Google Scholar. Finally, we searched South African HIV-1 sequence datasets not 
linked to a published article, using the PopSet database on the National Center for Biotechnology 
Information (NCBI) website.11  
 
We included studies involving adults (defined for the purpose of this analysis as 15 years or older) 
in South Africa with recent or chronic HIV infection and no documented prior ART exposure. We 
obtained information about prior ART exposure from either the article or the sequence annotation in 
GenBank. We excluded studies that enrolled women with documented exposure to antiretrovirals 
for prevention of mother-to-child transmission (pMTCT). We excluded studies with fewer than ten 
HIV-1 pol sequences; and studies where the sequences were generated from samples collected prior 
to 2000. Where articles reported on multiple separate cross-sectional studies (for example a series 
of annual antenatal surveys), we separated the sequences into individual datasets according to the 
sampling year. If results from the same study were presented in more than one publication, we 
pooled the sequences into a single dataset. We included sequences from one multi-national study,12 
as South African sequences could be identified through the sequence annotation in GenBank.  
 
From the articles, we retrieved a core set of information, including the year(s) of sample collection, 
province, study type, study population, proportion of participants that were female, and method for 
determining prior ART exposure.  
 
Sequence analysis 
We downloaded publicly available sequences for the included studies from GenBank.11 Where 
sequences were not publicly accessible, we contacted the study authors to request the sequences. 
We aligned and visually inspected the sequences in AliView v1.18 (http://ormbunkar.se/aliview/).13 
We manually edited the sequences until perfect codon-based alignments were produced. We 
assessed sequences for their completeness and quality using the Calibrated Population Resistance 
(CPR) tool (http://cpr.stanford.edu/cpr.cgi).14 Stop codons, frame-shift mutations, APOBEC3G/F 
hyper-mutations, highly unusual mutations and highly ambiguous nucleotides (B, D, H, V and N), 
were all used as indicators of poor sequence quality. We excluded from the analysis any sequence 
that did not meet the sequence inclusion criteria of the CPR tool. We included all sequences that 
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had complete reverse transcriptase gene (RT) sequences (codons 40 to 240), with or without 
complete protease (PR) sequences. Where multiple sequences were identified from the same study 
participant (for example in cohort studies), we only included the sequence from the earliest time 
point. Most sequences were not annotated with information about participant sex or age, so we did 
not include this information in the datasets. 
 
We defined PDR as the presence of any of 101 drug resistance mutations. The mutation list 
included the 93 mutations from the WHO 2009 list of surveillance drug-resistance mutations 
(SDRMs);15 and eight additional tenofovir resistance-associated mutations (TRAMs) characterised 
in a recent international collaborative analysis (A62V, K65N, S68GDN, K70QT, and V75L),16 
(appendix, p 4). Overall, the mutation list encompassed 42 nucleoside reverse-transcriptase inhibitor 
(NRTI) resistance mutations at 17 RT positions, 19 non-nucleoside reverse-transcriptase inhibitor 
(NNRTI) resistance mutations at ten RT positions, and 40 protease inhibitor (PI) resistance 
mutations at 18 PR positions. We used the CPR tool to calculate the proportion of sequences with 
overall and drug class-specific PDR.14 
 
Trends in pretreatment drug resistance 
To assess the annual increase in overall and drug class-specific PDR, we pooled sequences from 
different studies by year of sample collection and performed a generalized linear mixed regression 
model using the R package (v3.3.1) lme4. We used the presence or absence of PDR (or drug class-
specific PDR) as the binary outcome variable and the sampling year as the explanatory variable. 
Where samples from the same study had been collected over more than one year and where the 
sequence annotation did not include year of sample collection, we allocated the sequences to the 
median sampling year. To account for heterogeneity between studies, we included the dataset as a 
random effect in the model. Given the relatively small number of sequences with specific 
mutations, we also pooled the sequences into three periods (2000-2008, 2009-2012, and 2013-2016) 
and checked for any trend in prevalence of specific NRTI and NNRTI resistance mutations using 
the chi-squared test for trend.  
 
Results  
We initially identified 856 articles through our database search and nine articles through other 
sources. After removing duplicate publications, we screened 790 abstracts and assessed 46 full-text 
articles for eligibility. We excluded 14 articles on the basis of our eligibility criteria: eight contained 
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fewer than 10 HIV-1 pol sequences; two had only PR sequences with no RT sequences; one 
reported on a duplicate sequence dataset; one contained only sequences generated from samples 
collected prior to 2000; one was based on targeted sequencing for a single mutation (K65R); and 
sequences were unavailable for one study (appendix, p 5). From the 32 articles, we identified 38 
datasets with at least ten HIV-1 pol sequences from ART-naïve adults (Figure 1, Table 1, appendix, 
pp 6-9).7,8,23–32,9,33–42,12,43,17–22 Seventeen datasets were from formal surveys of pretreatment drug 
resistance or transmitted drug resistance.  
 
 
Figure 1 Flow diagram of articles and datasets identified and selected 
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Table 1 Characteristics of included datasets w
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We retrieved 7025 RT sequences and 6501 PR sequences. We excluded 145 RT sequences and 207 
PR sequences that did not meet sequence quality criteria. Therefore, we included 6880 RT sequences 
and 6294 PR sequences in the analysis (i.e. 6294 sequences with combined PR and RT and 586 with 
RT only) (appendix, pp 10, 11). The majority of sequences were subtype C (99·2%). Overall, 478 of 
6880 sequences (6·9%) had at least one drug resistance mutation. The majority of these sequences had 
only NNRTI resistance mutations (289/478, 60·5%); dual class NRTI and NNRTI PDR was present 
in 79/478 (16·5%) (appendix, p 12). The prevalence of overall and drug class-specific PDR in each 
dataset is displayed in Figure 2, and the crude pooled prevalence of overall and drug class-specific 
PDR by year is shown in Table 2.   
 
 
Figure 2 Prevalence of pretreatment HIV drug resistance by year of sampling 
 
A) Overall B) Non-nucleoside reverse-transcriptase inhibitor C) Nucleoside reverse-transcriptase 
inhibitor D) Protease inhibitor. Each bubble represents a dataset and the size of the bubble is 
proportional to the number of sequences in the dataset
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The prevalence of NNRTI PDR remained below 5% until 2011 and then increased rapidly to above 
10% by 2014. The pooled prevalence of NRTI PDR and PI PDR remained below 5% across all years. 
Over the entire study period (2000-2016), there was a 1·10-fold yearly increase in the odds of PDR 
(95% confidence interval (CI) 1·06-1·15), which was driven by increasing NNRTI PDR (odds ratio 
(OR) 1·18, 95% CI 1·13-1·23) and NRTI PDR (OR 1·10, 95% CI 1·05-1·16) (Table 3). 
 
Table 3 Annual change in odds of pretreatment HIV drug resistance, 2000 - 2016 
Drug Class Odds ratio (95% CI) p value 
NRTI 1·10 (1·05 – 1·16) 0·0001 
NNRTI 1·18 (1·13 – 1·23) <0·0001 
PI 0·96 (0·89 – 1·04) 0·3650 
Overall 1·10 (1·06 – 1·15) <0·0001 
CI, confidence interval; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, non-nucleoside 
reverse-transcriptase inhibitor; PI, protease inhibitor 
 
Overall, 374 sequences (5·4%) had at least one NNRTI DRM (appendix, p 13). The most prevalent 
mutation was K103NS, occurring in 278 sequences (58·2% of sequences with any DRM; 4·0% of all 
sequences) (Figure 3). In the majority of these sequences (218/278), K103NS was the only DRM. 
Other common NNRTI resistance mutations included V106AM (n=47), Y181C (n=34), K101EP 
(n=29) and G190AS (n=27). Overall, 77/374 (20·6%) had more than one NNRTI DRM, most 
commonly K103N + P225H (n=16) and K103N + V106M (n=12). The prevalence of some specific 
NNRTI resistance mutations increased over time. This trend was most marked for the K103NS and 
V106AM mutations, and less so for the K101EP mutations. There was no evidence of changing 
prevalence of Y181C or G190ASE  (appendix, p 14). 
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Figure 3 Prevalence of specific mutations in HIV-1 sequences with any drug resistance mutation. 
This includes all mutations observed in >1% of the sequences with any drug resistance mutation 
 
M184VI was the most common NRTI resistance mutation, present in 71 sequences (14·9% of 
sequences with any DRM; 1·0% of all sequences) (appendix, p 15). Most of the sequences with 
M184VI had at least one NNRTI DRM (66/71) and just under half had additional NRTI DRMs 
(31/71). The other NRTI DRMs accompanying M184VI included thymidine analogue mutations 
(TAMs, n=11), TRAMs (n=11), L74VI and/or Y115F (n=7), and other multi-NRTI mutations (n=2). 
Classical TAMs (M41L, D67N, K70R, L210W, T215FY, and K219EQ ) were detected in 36 
sequences (7·5% of sequences with any DRM; 0·5% of all sequences). The majority of these (30/36) 
had a single TAM; and eleven sequences had the M41L mutation alone without other DRMs. Overall, 
TRAMs were detected in 37 sequences (7·7% of sequences with any DRM; 0·5% of all sequences). 
The TRAM most frequently detected was K65R (n=21). Twelve sequences had a TRAM not on the 
WHO SDRM list (A62V, n=10; K70T, n=2), although in four of these sequences the mutation was 
present with the K65R mutation. The prevalence of TRAMs increased in later time periods: 0·1% 
(3/2480) in 2000-2008, 0·5% (11/2219) in 2009-2012, and 1·1% (23/2181) in 2013-2016, and for the 
M184VI mutation: 0·2% (4/2480) in 2000-2008, 0·9% (20/2219) in 2009-2012, and 2·2% (47/2181) 
in 2013-2016 (p<0·001, χ2 test for trend) (appendix, p 14). 
 
Fifty-six sequences (0·9%) had at least one PI DRM. The most frequently observed mutation was the 
relatively non-polymorphic M46IL mutation, which was detected in 35 sequences (0·6%) (appendix, 
p 16).  
 
Discussion 
In this pooled analysis with more than 6000 HIV-1 sequences from ART-naïve adults in South Africa, 
we observed a sustained increase in pretreatment HIV drug resistance between 2000 and 2016, driven 
primarily by NNRTI resistance. The increase in PDR seems to have accelerated since 2010, which 
coincides with the rapid expansion of ART coverage in the country from just 20% in 2010 to 56% in 
2016.44 By 2014, the pooled prevalence of NNRTI PDR had reached 10%, the threshold at which the 
WHO now recommends urgent public health action.45 There was also some evidence of increasing 
NRTI PDR, particularly tenofovir-associated resistance and the M184VI mutation associated with 
lamivudine and emtricitabine resistance. However, the pooled prevalence of NRTI resistance 
remained low (<5%) in each sampling year.   
 
These findings are consistent with those from recent meta-analyses exploring drug resistance across 
Africa, which showed levels of resistance rising to moderate levels about ten years into the scale-up 
of ART in the region.46,47 The overall 11% annual increase in odds of PDR between 2000 and 2016 in 
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South Africa is comparable to the 12% increase in odds of transmitted drug resistance across sub-
Saharan Africa between 2000 and 2013.46 The 18% annual increase in odds of NNRTI PDR is 
somewhat lower than the 24% reported for the southern Africa region in a more recent meta-
analysis.47 That could be explained by the fact that we only included ART-naïve adults, whereas the 
regional meta-analysis included a small number of sequences from people with prior ART exposure. 
Alternatively, it could be that the higher rate of increase in PDR in the regional meta-analysis was 
reflective of higher levels of PDR in other southern African countries. 
 
Our analysis was restricted to ART-naïve individuals and our assumption is therefore that transmitted 
drug resistance is the primary driver of the increasing PDR prevalence. There are limitations to this 
assumption, best illustrated by the most prevalent DRM, the K103NS mutation. This mutation, 
selected by efavirenz (EFV) and nevirapine (NVP), is the most common acquired NNRTI DRM in 
people with virological failure on standard first-line ART regimens in South Africa.48 Viruses with the 
K103NS mutation have transmission fitness similar to wild-type virus,49,50 and can persist for years in 
the infected host.51 It’s therefore entirely plausible that the high prevalence of this mutation is a 
consequence of frequent transmission. However, K103NS is also the most common mutation to 
emerge in women who receive single-dose NVP for the prevention of mother-to-child transmission 
and, in this context too, the mutation can persist for years in the absence of antiretroviral therapy.52,53 
Although we restricted the analysis to ART-naïve individuals, we could not be certain that 
participants in the individual studies were truly ART naïve. Most studies relied on self-report of 
antiretroviral use, which can be unreliable.54–59 Given that the majority of sequences were from 
women, it is possible that some of the NNRTI resistance arose from prior exposure to NVP for 
pMTCT rather than from transmitted drug resistance.  
 
We also revealed evidence of increasing NRTI resistance, at a rate similar to that observed in the 
larger regional meta-analyses.46,47 We specifically demonstrated increasing prevalence of TRAMs and 
the M184VI mutation, which is of some concern as tenofovir and emtricitabine/lamivudine remains 
the NRTI backbone of choice for first-line ART regimens. In the latter years (2013-2016), the pooled 
prevalence of the M184VI mutation was approximately 2% and the prevalence of TRAMs was 1%. 
Tenofovir and emtricitabine/lamivudine have been part of the standard first-line ART regimen in 
South Africa since 2010. The national drug resistance survey in 2013-14 showed that most people 
with virological failure on first-line NNRTI-based ART harboured the Met184Val/Ile mutation and 
about half had TRAMs.48 Whilst our findings could be a signal of increasing transmission of NRTI-
resistant virus, we urge some caution in interpretation. Viruses with the M184VI and K65R mutations 
are thought to be infrequently transmitted due to low transmission fitness.49,50 If they are transmitted, 
the mutations revert rapidly in the absence of drug pressure.51,60 It is possible that some of the 
sequences with NRTI resistance were obtained from people who reported themselves to be ART naïve 
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but who had previously been exposed to NRTIs. This is certainly plausible as there is an increasing 
frequency of cyclical engagement in care as ART programmes have matured.61 Somewhat against that 
was the observation that the prevalence of TAMs did not change and remained very low (<1%) 
throughout the study period, although this may be a reflection of the diminished use of stavudine and 
zidovudine in first-line regimens.  
 
We included a number of TRAMs that are not currently in the WHO SDRM list, but that are 
associated with TDF selection pressure.16 We did identify sequences with these TRAMs, in particular 
the A62V mutation, which was present both with and without the signature K65R mutation. Further 
work is required to understand the significance of these mutations and their effect on response to 
TDF-based regimens. 
 
Without appropriate action, PDR at the levels we have documented would be likely to have a 
significant impact on the HIV epidemic in South Africa. One mathematical model suggested that with 
PDR prevalence ≥10% and no change in the rates of resistance acquisition and transmission, 16% 
more AIDS deaths each year, 9% higher HIV incidence, and 8% higher ART costs would be 
attributable to drug resistance in Africa between 2016 and 2030.62 Once prevalence of NNRTI PDR 
exceeds 10%, the WHO recommends that national programmes consider switching to an alternative 
non-NNRTI first-line ART regimen.45 Many countries, including South Africa, have taken the 
decision to transition to a new first-line regimen of co-formulated generic tenofovir, lamivudine and 
dolutegravir (DTG).63 This is the option that mathematical models have predicted will mitigate the 
effects of HIVDR, will produce the most health benefits and a reduction in overall programme 
cost.64,65 However, there remain unanswered questions around DTG in the South African context, and 
strengthening of HIVDR surveillance and response systems will still be important to maximise the 
impact of the new regimen.66,67 
 
An alternative approach to the modified first-line ART regimen would be to introduce pretreatment 
HIVDR testing and shift towards individualised drug regimens.45 Whilst there is some evidence that 
HIVDR testing can be implemented in a research setting in South Africa,68 there is no evidence that it 
can be delivered cost-effectively through the public health system.  The shift towards more rapid 
initiation of ART (including same-day initiation) would make it particularly challenging to deliver 
pretreatment HIVDR testing. We still lack simple, rapid and inexpensive HIVDR assays, although 
there are promising technologies in development.69 Given the increasing complexity of HIV care and 
the uncertainty about the long-term effectiveness of DTG-based regimens, there is still a need to 
develop and evaluate HIVDR assays and pretreatment HIVDR testing strategies. 
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We believe it would be a mistake to think that modifying the first-line ART regimen is an adequate 
response on its own to the rising levels of PDR. Whilst there will clearly be a reduced risk of drug 
resistance emergence with DTG-based regimens, the public health approach to ART creates scenarios 
where the risk may be higher, particularly where DTG is the only fully active agent in the 
regimen.66,67 The increasing prevalence of PDR reflects weaknesses in prevention, treatment and care. 
Although South Africa implements routine viral load monitoring for people on ART, there are critical 
gaps in the viral load testing cascade and long delays in switching people with virological failure to 
second-line regimens.70 This means there is probably an expanding pool of people with acquired 
HIVDR who can then transmit drug-resistant virus to susceptible individuals. Our findings therefore 
support calls to focus on improving the quality of HIV services.71 This needs to be rooted within a 
broader multisectoral response, informed by high quality transdisciplinary research, that addresses the 
social and structural drivers of the epidemic.72 
 
Interpretation of our findings should be subject to some limitations beyond those already discussed. 
Firstly, certain provinces were over-represented in our analysis, particularly KwaZulu-Natal and 
Gauteng, and estimates from the latter years were dominated by two large population-based 
surveillance studies from KwaZulu-Natal. Findings from the national PDR survey in 2013-14 
suggested substantial heterogeneity between the provinces in levels of PDR, and therefore our 
estimates may not reflect the situation throughout the country.8 Secondly, we pooled results from a 
number of individual studies, not all of which were designed to evaluate PDR. We did not account for 
individual study design in our analysis and derived only pooled crude estimates of prevalence. Our 
estimates should therefore not be taken to represent population prevalence. Lastly, we analysed only 
sequence data and were unable to explore differences by sex, age, CD4+ cell count, and duration of 
infection, as this information was not available for the majority of sequences.  
 
In conclusion, we present evidence that the prevalence of PDR has risen substantially in South Africa 
in the past few years. Whilst this is predominantly NNRTI resistance, there is also evidence of rising 
levels of resistance to tenofovir and lamivudine/emtricitabine, although the absolute prevalence of 
PDR to these drugs remains low. Our findings support the decision to transition to a new, DTG-based 
first-line ART regimen. If the association between neural tube defects and DTG is confirmed, and 
NNRTIs continue to be recommended for women of childbearing age,73 this evidence would suggest 
the need for additional interventions, such as pre-treatment genotypic resistance testing or early VL 
testing. These findings also highlight the need for broader strengthening of HIV services within the 
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The manuscript in chapter 4 describes increasing levels of PDR in South Africa, most marked from 
2010 when ART rollout was scaled-up, highlighting the decision to adopt a new first-line regimen 
that does not contain NNRTIs. However, changing regimens alone is only one key factor in 
addressing the glaring gaps challenging the ARV programme, viz, drug stock-outs, inadequate viral 
load monitoring and access to baseline resistance testing limited to research settings, amongst 
others. Currently, there is limited knowledge on the impact of DRMVs which are not reliably 
detected by Sanger sequencing, but could be selected for following ART initiation due to selective 
drug pressure. NGS has the ability to detect these DRMVs, but their clinical relevance is not well 
understood. The following manuscript is based on a study that aimed at assessing if standard 
genotypic resistance testing underestimates pretreatment resistance, and the impact DRMVs on 
clinical outcomes. This included testing the sensitivity and specificity of HIVDR thresholds in 













CHAPTER 5: IMPACT OF PRE-TREATMENT DRUG RESISTANT MINORITY 





































Impact of HIV pretreatment drug resistant minority variants on antiretroviral therapy 
outcomes in HIV/TB co-infected patients 
 
Benjamin Chimukangara,1,2,3* Jennifer Giandhari,1 Richard Lessells,1 Nonhlanhla Yende,2 Benn 
Sartorius,4,5 Reshmi Samuel,3 Babill Stray-Pedersen,6 Pravi Moodley,3 Karin Metzner,7 Kogieleum 
Naidoo,2,8 and Tulio de Oliveira1,2  
 
Affiliations: 
1. KwaZulu-Natal Research and Innovation Platform (KRISP), College of Health Sciences, 
University of KwaZulu-Natal, Doris Duke Medical Research Institute, Durban, South Africa 
2. Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, 
Durban, South Africa 
3. Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal, 
Durban, South Africa  
4. Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, 
Durban, South Africa 
5. Health Metrics Sciences, University of Washington, Seattle, USA 
6. Institute of Clinical Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway 
7. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University 
of Zurich, Zurich, Switzerland 
8. South African Medical Research Council (SAMRC), CAPRISA HIV-TB Pathogenesis and 
Treatment Research Unit, Durban, South Africa 
 
*Corresponding author:  
Benjamin Chimukangara  
KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) 
School of Laboratory Medicine and Medical Sciences 
University of KwaZulu-Natal 
719 Umbilo Road 
Durban, 4001 
South Africa 
Tel: +27-31-260-4898,  
Email: benjiechim@gmail.com  
 





Objectives: To determine the impact of pretreatment drug resistant minority variants (DRMVs) on 
virological response to antiretroviral therapy (ART), and assess how thresholds of pre-ART DRMVs 
predict treatment failure.  
 
Methods: A case-control study using plasma samples from adult HIV/TB co-infected patients. Cases 
were patients with confirmed viral loads ≥1,000 copies/mL after ≥6-months on ART, and controls 
were patients that achieved virological suppression throughout 24-months of ART follow-up. Samples 
were sequenced by Sanger sequencing and Illumina MiSeq next generation sequencing (NGS). 
Mutations were assessed using the Stanford HIV drug resistance database, and were analyzed at 2%, 
5%, 10% and 20% thresholds. Associations between drug-class resistance and treatment response 
were assessed, and predictive accuracy of pre-treatment resistance for prediction of subsequent ART 
failure was estimated.  
 
Results: Samples from 177 patients were analyzed (52 cases and 125 controls). Drug resistance 
prevalence was 6.2% (11/177) at pre-ART (i.e. 5 cases and 6 controls) by Sanger sequencing and 
NGS at 20%. The prevalence increased to 23.2% (41/179) when DRMVs at 2% were included (i.e. 14 
cases and 27 controls). NNRTI-DRMVs at 5% were associated with ART failure (P=0.02). Lowering 
the detection threshold reduced the specificity from 97% (CI: 92-99) at 20%, to 93% (CI: 87-97) at 
5% threshold. 
 
Conclusions: NNRTI-DRMVs affect virological response to ART. NGS improved detection of drug 
resistance, but reduced the ability to identify patients at risk of virologic failure at lower thresholds. 
More studies assessing mutation thresholds predictive of virologic failure are required to inform use 















South Africa is one of the countries most affected by HIV and has the largest antiretroviral therapy 
(ART) program globally.1 Tuberculosis remains the leading cause of death in people living with HIV 
in low- and middle-income countries (LMICs) such as South Africa.2,3 HIV/TB co-infected patients 
have a higher risk of failing ART due to increased pill burden, overlapping toxicities, and 
programmatic challenges in integrating HIV/TB-care services.3–6 This also increases their chances of 
developing HIV drug resistance (HIVDR).  
 
Sanger sequencing has been the conventional method used for detecting HIVDR mutations, but it 
does not reliably detect mutations that occur at <20% of the viral population,7 i.e. variants that are not 
well represented in the viral quasispecies. Various NGS platforms have been developed over the 
years, using different chemistries,8 but all have the ability to produce high throughput data at 
relatively lower costs compared to Sanger sequencing, and have the ability to detect low frequency 
viral variants, also known as drug resistant minority variants (DRMVs).8 However, the clinical impact 
of the DRMVs on clinical outcomes remains unclear and understudied in HIV-1 subtype C, and in 
HIV/TB co-infected patients.  
 
A few studies have shown that pretreatment non-nucleoside reverse transcriptase inhibitor (NNRTI)-
DRMVs have an impact on NNRTI-based ART outcomes,9–13 whilst the CASTLE study (a 
prospective study in patients on first-line ART) showed no significant effect of transmitted DRMVs 
on PI-based regimens,13 suggesting lack of adherence as a major cause of ART failure rather than 
pretreatment DRMVs.14 Such inconsistencies warrant further research on DRMVs, if NGS 
technologies are to be used in routine clinical practice to inform treatment decisions. In this study we 
sought to assess the impact of pre-ART DRMVs at different thresholds in a cohort of HIV/TB co-
infected patients (using NGS and Sanger sequencing), by comparing pretreatment drug resistance 
(PDR) profiles in patients that achieved viral suppression on ART to those that experienced virologic 
failure. 
 
Patients and Methods 
Ethics 
This research study was approved by the Biomedical Research Ethics Committee of the University of 
KwaZulu-Natal (reference number: BF340/17). Ethical approval for the SAPiT (reference number: 
E107/05) and TRuTH (reference number: BF051/09) studies was obtained from the Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal, and participants gave informed 




Study design and study population 
This was a nested case-control study aimed at assessing the impact of pretreatment DRMVs on ART. 
De-identified remnant plasma samples were obtained from a representative sample of HIV/TB co-
infected adults (>18 years) from the Starting Antiretroviral therapy at three Points in Tuberculosis 
(SAPiT) trial. The study was an open-label, randomized, controlled trial conducted by the Centre for 
AIDS Programme Research in Africa (CAPRISA) between June 2005 and July 2008, at the 
eThekwini Clinical Research Site (ECRS) in Durban, South Africa. The study investigated the effect 
on mortality of antiretroviral therapy started during TB treatment (in two integrated-therapy groups) 
or after the completion of TB treatment (in one sequential-therapy group). Some SAPiT participants 
who went on to develop virological failure were identified through a subsequent study known as the 
TB Recurrence upon Treatment with HAART (TRuTH). Details of the SAPiT and TRuTH studies 
have been published previously.15–18  
 
Samples from adult HIV/TB co-infected participants were selected in a 1:2 case control ratio. The 
cases included all participants enrolled in the SAPiT trial who had at least one viral load (VL) ≥1,000 
copies/mL after ≥6 months on ART. The controls were unmatched randomly selected participants 
enrolled in the SAPiT trial who had 6-monthly VL’s <1,000 copies/mL throughout follow-up for 24 
months. The cases had two samples each, one at ART initiation (pre-ART) and another at virologic 
failure (ART failure), whilst the controls had only one sample from the pre-ART time-point. In cases 
where samples were not available at first high VL, a subsequent sample was accessed based on 
availability of remnant plasma.  
 
Laboratory methods 
Samples with VL ≥1,000 copies/mL were obtained for drug resistance testing. In summary, stored 
plasma samples were retrieved from storage at -80oC and thawed to room temperature prior to viral 
RNA extraction. For each sample, 500ul of plasma was centrifuged at 23,000g for 1 hour at 4oC to 
pellet the virus. Viral RNA was extracted from 200ul of pelleted plasma using a NucliSens EasyMAG 
HIV-1 (bioMerieux, France) extraction system. Protease (PR) and reverse transcriptase (RT) gene 
amplification was done using Southern African Treatment Resistance Network custom primers, as 
described previously.19 Successfully amplified polymerase chain reaction (PCR) products were 
purified using a Qiagen PCR purification kit (Qiagen, Germany), according to manufacturer’s 
instructions. To limit sample variability in final sequencing product, purified PCR products of each 
sample were aliquoted for sequencing using Sanger sequencing and NGS.  
 
Sanger sequencing 
In preparation for capillary electrophoresis, sequencing reactions were done using a BigDye 
Terminator v3.1 kit (Applied Biosystems, Foster City, CA, USA), and sequence reaction purifications 
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using a BigDye XTerminator v3.1 purification kit (Applied Biosystems, Foster City, CA, USA), 
according to manufacturer’s instructions. Capillary electrophoresis was done on a ABI 3730 genetic 
analyzer and the quality of sequences was assessed using Geneious software v8.1.9 (Biomatters Ltd, 
New Zealand).20 Sequences with incomplete PR (codons: 1-99) and RT (codons: 1-254) genes were 
excluded as having poor sequence quality. Drug resistance mutations were detected using the Stanford 
University HIV drug resistance database.21  
 
Next generation sequencing  
For NGS, PCR product concentrations were determined using a Qubit 3.0 fluorometer (Life 
Technologies, Malaysia). The amplicons were diluted to 0.2ng/ul and library preparation was done 
using the Nextera-XT DNA Library Preparation kit and Nextera Index kit (Illumina, San Diego, CA, 
USA), according to the manufacturer’s instructions. In summary, library preparation involved kit-
based enzymatic fragmentation of DNA, dual indexing of fragmented DNA, and bead-based 
purification of amplicons using AMPure beads (Beckman Coulter, Brea, CA, USA). Quality control 
steps were carried out using the LabChip GX Touch (PerkinElmer, Hopkinton, MA, USA) to 
determine the amplicon size, and library concentrations were determined by Qubit 3.0 fluorometer 
(Life Technologies, Malaysia). Each sample library was normalized to 4nM concentration and the 
normalized libraries were pooled and diluted to a final concentration of 10pM. The library at 10pM 
concentration was spiked with 5% PhiX control and run on an Illumina MiSeq platform (Illumina, 
San Diego, CA, USA) using the MiSeq Nano Reagent Kit v2 for 500 cycles.  
 
Paired end sequencing analysis was done using the Polymorphism Analysis Sequencing (PASeq) 
software, which is a web-based accessible cloud based system (https://paseq.org/). In summary, the 
software used Trimmomatic for quality control in filtering sequences and for adapter trimming, and 
checking for external contamination. Gene coverage plots were generated, calling of deep variants 
was done, and querying of the Stanford HIVdb program with consensus sequence was done to assess 
resistance mutations. A report of the variants was provided with interpretations at different thresholds. 
The quality of NGS sequences was assessed in PASeq software and the depths of coverage were 
assessed in Genome Detective,22 a web-based tool for analysis of molecular sequence data 
(https://www.genomedetective.com). Sequences with <1,000X depth of coverage or having 
incomplete PR (codons: 1-99) and RT (codons: 1-254) genes, were excluded as having poor sequence 
quality. 
 
Drug resistance was defined as having a major PI resistance mutation, NRTI resistance mutation or a 
NNRTI resistance mutation. Patients with failed HIV genotyping at either time-point were excluded, 
in order to analyze complete sequence pairs from pre-ART to ART failure. Resistance mutations were 




Statistical analysis was done using STATA v13 (StataCorp, College Station, TX, USA). We used the 
Fisher Exact test and Wilcoxon rank sum test (for categorical and continuous covariates respective) to 
compare baseline demographics (i.e. sex and age) and clinical characteristics (CD4 count, viral load, 
months on ART and SAPiT randomization arm) between cases and controls. Fisher’s exact test and 
exact logistic regression were used to assess associations between participant demographic and 
clinical characteristics, and ART failure. The predictive accuracy of the different pre-ART thresholds 
in determining subsequent ART failure were assessed and presented as measures of sensitivity and 
specificity. Sensitivity represents the accuracy of the threshold in detecting patients that have pre-
treatment drug resistance who experience virologic failure. Specificity represents the accuracy of the 
threshold in detecting patients that do not have pretreatment drug resistance who maintain virologic 
suppression.  
 
Results   
Participants characteristics 
Two hundred and ninety samples were obtained from 214 participants, i.e. 152 case samples (from 76 
participants) and 138 control samples. Two hundred and fifty-five of 290 samples were successfully 
amplified and 229 had complete NGS and Sanger sequence pairs; 104 case samples (from 52 
participants), and 125 control samples (Figure 1). 

































a Cases included all participants enrolled in the SAPiT trial that had viral 
loads ≥1,000 c/ml after ≥6 months on ART 
 
b Controls were randomly selected from SAPiT trial participants to match 
cases at a 1:2 ratio 
 
            
      
     
	
Participants included in final analysis 




Participants with unsuccessful HIV 
genotype (n = 37) 
 
Failed amplification (22) 
Poor sequence quality (15) 
 
Participants selected 
(n = 214) 
 
Cases (76) a 
Controls (138) b 
 
Participants in SAPiT trial  
(n = 642) 
 
(n =  290) 
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Figure 1 Summary flow chart of participants from selection to analysis  
All sequences were HIV-1 subtype C. All except 2 participants (175/177) received efavirenz (EFV), 
with lamivudine (3TC) and didanosine (ddI) at ART initiation. Table 1 summarizes the demographic 
and clinical characteristics of the participants included in the final analysis. No significant differences 
in these demographic and clinical characteristics were observed when comparing cases and controls. 
 











Female, n (%) 103 (58.2) 33 (63.5) 70 (56.0) 0.41 
Age in years at baseline, median (IQR) 34 (29-40) 35 (27-39) 34 (29-42) 0.47 
Viral load (log10 copies/mL) at baseline, 















(78 - 228) 
0.22 
Months on ART before virologic failure, 
median (IQR)  
- 16  
(9-37) 
- - 
Treatment arms     
  Early, n (%) 52 (29.4) 14 (26.9) 38 (30.4) 0.80 
  Post-intensive, n (%) 67 (37.9) 19 (36.5) 48 (38.4)  
  Post continuation, n (%) 58 (32.8) 19 (36.5) 39 (31.2)  
ART, antiretroviral therapy; CD4, cluster of differentiation 4; IQR, interquartile range; 
a1 case and 2 controls with missing viral loads at pre-ART 
 
Pre-ART resistance data 
Overall, of 177 pre-ART sequences, 11 (6.2%) had at least one drug resistance mutation detected by 
Sanger sequencing and NGS at 20% (5 cases and 6 controls). All except one sequence (case) had 
single-class resistance at pre-ART, and the most common major mutation was K103N, which was 
detected in 4 of 11 sequences with NGS resistance at 20%. When DRMVs were included in the 
analysis, the levels of pre-ART drug resistance increased from 1.1% (at 20%) to 6,2% (at 2%) for PIs, 
from 1.1% (at 20%) to 11.9% (at 2%) for NRTIs, and from 4.5% (at 20%) to 9.0% (at 2%) for 
NNRTIs. Table 2 summarizes the pre-ART drug-class mutations observed by NGS at different 




Table 2. Proportion of pre-ART drug-class resistance by NGS mutation thresholds 
 Detection threshold 
 2% 5% 10% 20% 
Overall resistance (n=177)     
Any resistance, n (%) 41 (23.2) 19 (10.7) 14 (7.9) 11 (6.2) 
Any PI major resistance, n (%)  11 (6.2) 5 (2.8) 2 (1.1) 2 (1.1) 
Any NRTI resistance, n (%) 21 (11.9) 7 (4.0) 5 (2.8) 2 (1.1) 
Any NNRTI resistance, n (%) 16 (9.0) 9 (5.1) 8 (4.5) 8 (4.5) 
Controls (n=125)     
  PI major resistance, n (%) 9 (7.2)  4 (3.2) 2 (1.6) 2 (1.6) 
  NRTI resistance, n (%) 12 (9.6) 4 (3.2) 4 (3.2) 1 (0.8) 
  NNRTI resistance, n (%) 9 (7.2) 3 (2.4) 3 (2.4) 3 (2.4) 
Cases (n=52)     
  PI major resistance, n (%) 2 (3.9) 1 (1.9) 0 (0) 0 (0) 
  NRTI resistance, n (%)      9 (17.3) 3 (5.8) 1 (1.9) 1 (1.9) 
  NNRTI resistance, n (%) 7 (13.5) 6 (11.5) 5 (9.6) 5 (9.6) 
PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; ART, antiretroviral therapy 
 
The proportion of DRMVs were determined at variant frequency thresholds of <20%. Thirty of 177 
(17.0%) pre-ART sequences had DRMVs only, with no mutations at 20%. DRMVs by drug class 
proportion at pre-ART were as follows: 4.5% (8/177) for PIs (1 case and 7 controls), 10.2% (18/177) 
for NRTIs (7 cases and 11 controls), and 4.0% (7/177) for NNRTIs (2 cases and 3 controls). The most 
common DRMV at pre-ART was the K65R mutation, occurring in 6 of 177 (3.4%) sequences. The 
median frequency of K65R at pre-ART was 2.8% (interquartile range (IQR): 2.2 – 3.6), occurring as 
the only mutation in 5 of the 6 sequences. Pre-ART NNRTI resistance at 5% was significantly 
associated with ART failure (P=0.02; OR: 5.3). Figure 2 shows the prevalence of pre-ART DRMVs 




Figure 2 DRMVs observed in sequences with pre-ART resistance 
 
ART failure resistance data 
At ART failure, 78.9% (41/52) of sequences had drug resistance mutations detected at 2%, with 
73.1% (38/52) having drug resistance at 20%. Seven of the 52 cases had switched from a NNRTI- to a 
PI-based regimen at time of virologic failure, and only 2 of the 7 had drug resistance mutations at 
20%, with no PI resistance mutations observed (Supplementary Table S1). The median time on ART 
was 16 months (IQR: 9-37), and there was no significant association between duration on ART and 
presence of drug resistance mutations at 20% (P=0.58). Sex, age, CD4 counts and VLs were not 
significantly associated with ART failure (Supplementary Table S2).  
 
Twenty-seven of 52 (51.9%) had dual-class resistance and 11 (21.2%) had single class resistance at 
20%, at ART failure. The most common major NNRTI mutation at ART failure was V106M, 
occurring in 44.2% (23/52) of sequences, whilst M184VI was the most common NRTI mutation, 
occurring in 40.4% (21/54) of sequences, with no PI mutations detected at ART failure. There was no 
clear trend in selection of DRMVs between pre-ART and ART failure time-points, with only 4 of the 
52 cases having pre-ART DRMVs occurring at 20%, at ART failure. The mutations selected for were 
NRTI mutations, K65R, D67N and L74I, and an NNRTI mutation V106AI, which occurred as a 
V106M mutation at ART failure (Supplementary Table S3).  
 
Predictive accuracy of pre-ART resistance 
We tested accuracy measures of the different thresholds in determining treatment failure outcome. 























































































confidence interval (CI): 3-20) to 33% (95% CI: 21-48), with a reduction in specificity from 97% 
(95% CI: 92-99) to 79% (95% CI: 71-86). Among participants classified as having resistance at 2% 
threshold, 40.9% (18/44) went on to experience virologic failure, whilst among those below this 
threshold 73.3% (99/135) maintained viral suppression on treatment. We observed a large reduction 
in specificity when shifting from the 5% to 2% threshold (93% to 79%) with a corresponding 3-fold 
increase in sensitivity (11% to 33%). However the 20% threshold showed the highest discriminative 
power (maximum diagnostic odds ratio) as shown in Table 3.  
 
Table 3 Measures of sensitivity and specificity of pretreatment drug resistance thresholds  
DRM threshold Sensitivity Specificity Diagnostic OR 
20% 9% (3-20) 97% (92-99)  3.1 (0.9-11.1) 
10% 9% (3-20) 94% (89-98) 1.7 (0.6-5.4) 
5% 11% (4-23) 93% (87-97) 1.6 (0.6-4.6) 
2% 33% (21-48) 79% (71-86) 1.9 (0.9-3.9) 
  DRM, drug resistance mutation; OR, odds ratio 
 
Discussion 
NGS increased detection of resistance at pre-ART, and showed high concordance for detecting 
mutations at 20% when compared to Sanger sequencing. Pre-ART NNRTI resistance at 5% showed a 
significant association with developing virologic failure on ART. This is similar to previous studies 
that suggest NNRTI-DRMVs impact ART outcomes,9,23,24 but is also contradictory to studies such as 
the OCTANE 2 trial,25 which showed no impact on ART, with a recent study from the ANRS 12249 
trial showing dual-class resistance (NRTI and NNRTI) prolonging time to viral suppression, rather 
than NNRTI resistance alone.26 However, measures of predictive accuracy of each drug resistance 
threshold showed reduced specificity from 97% (CI: 92-99) at 20%, to 93% (CI: 87-97) at 5%, with a 
further reduction to 79% (CI: 71-86) at 2%. These results are relatively consistent with a multi-
country nested case control study that showed the specificity reduce from 98% (CI: 95-99) at 20% 
threshold, to 96% (CI: 92-98) at 5% threshold.27 Such reductions in specificity will have huge cost 
implications especially in LMICs which have the highest numbers of patients requiring ART, and 
could pose challenges to ART programs, in maintaining optimal treatment monitoring and retention of 
patients in care.  
 
Notably, K65R was the most common DRMV, occurring at only 2% threshold in all 6 sequences with 
the K65R mutation at pre-ART. Considering the mutation occurred at very low frequencies at pre-
ART and was not readily selected by ART drug pressure, there is a chance the K65R DRMVs (i.e. at 
2%) detected resulted from PCR and sequencing errors.28,29 Previous studies have shown that HIV-1 
subtype C is more likely to develop the K65R mutation due to a homopolymeric region between RT 
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codon positions 63 and 65. This causes preferential pausing of the RT enzyme at the “AAG-to-AGG” 
position, resulting in dislocation mutagenesis that causes the K65R mutation.30 However, the stringent 
quality control measures in trimming sequences, and including only sequences with >100X coverage, 
increased the confidence in calling mutations at low frequencies, up to 2%. K65R was also the third 
most common NRTI mutation at ART failure, which is concerning as it causes intermediate to high-
levels of resistance to almost all NRTIs except AZT, and importantly, high-levels of resistance to 
tenofovir (TDF),21 a drug that has become the main NRTI agent in current and future first-line 
regimens.31 High rates of K65R DRMVs have also been reported recently in a Malawian cohort,32 and 
previously as major mutations in South African patients failing first-line ART,33,34 warranting further 
research on pre-ART K65R mutations.  
 
Interestingly, NNRTI mutations had the least pre-ART DRMVs, but the most prevalent major 
mutations at pre-ART and at ART failure (Figures 2). The most common NNRTI mutations at ART 
failure occurred at positions where mutations are known to be highly selected for by EFV (i.e. 
positions 103, 106, 188 and 190).21 High-levels of NNRTI resistance in first-line ART failures have 
been reported previously in a South African national survey,34 with common mutations at positions 
103 and 106. Among participants failing ART on PIs with no major mutations and good ART 
adherence, investigating linked-mutations outside the pol gene could determine the cause of failure, as 
previous studies have shown mutations in Gag cleavage sites 35,36 that are linked with PI-resistance. 
This suggests utility of whole genome sequencing in people failing ART.  
 
This study had limitations which should be taken into consideration when interpreting these findings. 
The proportion of participants with pre-ART NNRTI-DRMVs at 5% was quite similar to those with 
mutations at 20% (Figure 1), reducing our certainty in associating NNRTI-DRMVs at 5% to ART 
failure. The similarity could suggest major mutations as the main contributor to ART failure, rather 
than the mutations at 5% threshold. Another limitation was the lack of participant drug concentration 
levels to definitively show that they were taking their treatment at time of ART failure. However, 
intensive counseling and adherence support were provided to the study participants, with an 
approximately 97% adherence rate according to monthly pill counts, as reported previously.15 This 
would suggest adequate drug pressure for the selection of mutations, making the study population 
ideal to assess impact of pretreatment DRMVs on ART. However, factors such as drug-drug 
interactions, and GI toxicity leading to malabsorption could have affected the ability to determine the 
effect of the mutations on ART outcomes, warranting further research in HIV/TB co-infected patients. 
 
Most participants in this study initiated ART on ddI, a drug that is not commonly used in current 
regimens. This is because remnant plasma samples were used in order to identify a significant number 
of HIV/TB co-infected patients that initiate and fail treatment at a later time-point. However, EFV 
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remains a common first-line regimen for the foreseeable future,37 despite recommendations to switch 
to dolutegravir (DTG), a cheaper and better tolerated antiretroviral drug.38,39 This is because of the 
risk of neural tube birth defects when DTG is used in pregnancy,31,40 as well as the lack of evidence 
supporting use of DTG in patients on HIV/TB treatment.41 The INSPIRING study has shown good 
efficacy and safety of twice daily DTG in HIV/TB co-infected adults treated with rifampicin.42 
However, more studies on use of DTG in HIV/TB co-infected patients and in women of child bearing 
potential are required.43  
 
The participants had a relatively short follow-up period, median 16 months (Table1) on ART, as 
determined by the parent study.15 Long-term follow-up is suggested in future studies, and more 
studies in individuals on recent regimens are required, to assess the importance of these DRMVs, 
regardless of the introduction of INSTIs. Lastly, we excluded 37 participants (Figure 1) due to failed 
amplification and poor sequence quality, most of which were case samples (24/37). This could have 
affected the sensitivity, given the smaller number of ART failure events when stratified by thresholds. 
Larger studies testing these diagnostic measures are required.  
 
In conclusion, NNRTI-DRMVs have the potential to cause ART failure. These results suggest that a 
detection threshold of 5% in NNRTI pre-ART resistance could be considered to inform treatment 
response. However, more research is required to determine an optimal threshold that could be used for 
predicting virologic failure. Our findings add to the paucity in knowledge around the impact of 
DRMVs on ART, and suggest the need for studies addressing this research question.  
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CHAPTER 6: SYNTHESIS OF RESEARCH FINDINGS 
 
6.1 Key Themes 
Surveillance for HIVDR remains an integral part of successful ART programs. Attempts to treat HIV, 
without monitoring viral response to ART regimens, may be undermined by development of drug 
resistant virus, an inevitable phenomenon in any setting where ART is used. More people with HIV 
infection have been initiated on ART following the adoption of the UTT strategy. However, the 
supporting structures of ART programs seem to be failing due to the increasing demands of an 
extensive ART roll-out, especially in LMICs like South Africa. This is due to challenges such as 
reaching HIV positive individuals, testing and initiating them on ART, having continual linkage and 
retention in care, maintaining consistent access to ARV drugs and viral load testing, adherence 
support, and a timely response to switching patients to effective ART regimens once they develop 
treatment failure (Figure 11). Achieving all these steps in the cascade of care is challenging, 
especially in an HIV epidemic, such as in South Africa, and strengthening of the healthcare systems is 
imperative to the control of HIVDR. 
 
 
Figure 11 Healthcare system challenges in the HIV prevention, treatment and care  
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However, KPs face multiple challenges 
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Figure 1  |   The Leaky Pipe of the HIV Continuum of Prevention, Care, and Treatment Cascade
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The weaknesses of the health care system are evident by the increasing levels of drug resistance 
presented in chapters 3 and 4. Results presented in these chapters show that PDR levels exceeded 
10% by 2014 in South Africa, the threshold considered by the WHO as indicating the need for urgent 
public health action. The public health action entails replacing NNRTI drugs in first-line ART once 
NNRTI-PDR has reached ≥10%, or testing for drug resistance mutations in all HIV positive people, 
before initiating them on ART. Drug resistance testing is costly and is available as a specialized test in 
most LMICs. One of the major limitations to the analysis of PDR was the lack of information on drug 
concentration levels from the different studies. Such information is important to determine prior ART 
exposure. However, considering that drug concentration level tests are not done in routine practice 
when people are initiated on ART, these results are still representative of the general population of 
people that are initiated on treatment as ART naïve. Furthermore, there is a high burden of HIV in 
South Africa, where approximately 270,000 new HIV infections occurred in 2017 [8]. Thus, changing 
the standard first-line ART regimen may be a more feasible option to pretreatment drug resistance 
testing and drug concentration level tests. Additionally, the levels of PDR exceeded the WHO critical 
threshold approximately 4 years before the findings were actually reported, which suggests that 
implementation of routine HIVDR surveillance in South Africa is needed to proactively identify such 
outcomes more rapidly, such as with the roll-out of DTG in the public sector.  
 
In addition to surveillance monitoring, rapid switching of regimens in patients with virologic failure 
on TDF/FTC/EFV (TEE) is essential to reduce the risk of TDF-resistance associated mutations 
(TRAMs) developing and being transmitted. This is supported by phylogenetic results presented in 
chapter 3, suggesting that, most drug resistance transmission events are occurring from treatment 
experienced to treatment naïve individuals. Despite the noticeable increase in PDR shown in chapter 
4, including that of NRTIs, the levels of TDF resistance remained relatively low over the years. 
However, when separated into three time periods (i.e. 2000 to 2008, 2009 to 2012 and 2013 to 2016), 
the levels of TRAMs increased significantly over time, prompting further research to understand 
whether or not this increase was due to transmission of TRAMs, or due to more people cycling in and 
out of care. This is of concern for DTG-based ART, as TDF is the main NRTI-backbone in current 
first-line regimens and in the impending DTG-based ART regimen, which will constitute 
TDF/3TC/DTG (TLD) [95]. This further emphasizes the need for surveillance of TDF resistance, 
especially among people already on TEE, as high-levels of the K65R mutation that confers resistance 
to TDF have been reported previously [96,97]. We included the M46I/L mutation in the analysis of 
sDRMs in chapter 3 despite the revision in the WHO global report in 2012 excluding the mutation. 
This could have slightly over estimated the levels of PI resistance, but still includes all possible 
mutations that could confer resistance to LPV/r and ATV/r, commonly used PI drugs in South Africa. 
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The results in chapter 5 show K65R as the most common DRMV at pre-ART, occurring at only 2% 
threshold. It has been suggested previously that subtype C virus is more prone to develop this 
mutation due to a homopolymeric region ending in the K65R position. This causes preferential 
pausing of the reverse transcriptase enzyme at the “AAG-to-AGG” position, resulting in dislocation 
mutagenesis that causes the K65R mutation [98]. Moreover, as the detection threshold is reduced, the 
chances of sequencing errors which could result in inaccurate mutation calls increases [99], which 
could explain the lack of selection of the mutation under drug pressure, as shown in chapter 5. 
However, the stringent quality control measures taken in trimming sequences, as well as including 
only sequences with a sequencing depth >100X, increased the confidence in calling mutations at low 
frequencies, up to 2% threshold. It is possible that these K65R DRMVs are the reason why patients 
failing on TDF-based ART in South Africa have high rates of K65R mutations [96,97], suggesting 
potential selection of the K65R DRMVs to become major resistance mutations at ART failure, due to 
drug pressure. Unfortunately, the study in chapter 5 could not support this hypothesis as only one 
patient had a pre-ART K65R DRMV selected for to become a major mutation at ART failure. 
 
However, the study did show that as the detection threshold is reduced to <20%, more mutations are 
detected, at the expense of correctly predicting which patients will fail treatment. The paper shows a 
reduction in specificity from 97% (92-99) at 20% threshold, to 94% (89-98) at 10% threshold, to 93% 
(87-97) at 5% threshold, and to 79% (71-86) at 2% threshold. Therefore, reducing the detection 
threshold increases the chances of detecting more drug resistance mutations, but the mutations do not 
seem to affect virologic response to ART. Therefore, the accuracy of resistance as a predictor of 
virologic failure, decreases with a reduction in the detection threshold. Similar findings were 
described by a hypothetical case [100], which suggested that reducing the detection threshold from 
20% to 1% could result in a 300% increase in patients misclassified as likely to fail treatment [100]. 
Therefore, in a population of 100,000 patients starting treatment, 5400 patients with mutations at 1% 
threshold will be incorrectly predicted as patients likely to fail ART, which may have huge cost 
implications as more people might not benefit from cheaper first-line drug options, if low frequency 
mutations are considered. Thus in South Africa which has a high HIV prevalence and where standard 
ART regimens are used for treatment initiation, careful consideration of the benefits and shortcomings 
of detecting DRMVs is vital for public health decision making.  
 
The paper in chapter 5 also showed that having any pre-ART NNRTI resistance (at ≥2%) was 
significantly associated with ART failure, although cautious interpretation of the effect of the DRMVs 
is required, considering that only a few patients had pre-ART NNRTI-DRMVs occurring without 
mutations at 20%. These results are consistent with previous studies (in non-TB patients) showing 
that NNRTI-DRMVs are associated with ART failure [78–80,101]. However, there are conflicting 
findings regarding the impact of these mutations in different settings. In contrast to the OCTANE 
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Trial 1, which demonstrated an increased risk of virologic failure due to underlying K103N and 
Y181C DRMVs in patients initiated on NVP-based first-line ART following single-dose nevirapine 
exposure for prevention of mother-to-child transmission of HIV [102], the OCTANE Trial 2 showed 
no such effect of DRMVs on ART [103]. Thus understanding the impact of DRMVs on ART is 
complex and may not be properly explored in a single study but through incremental studies in 
different contexts, involving patients with different clinical characteristics. For example, some 
mutations can be selected for more than others, due to their low fitness cost, whilst the effect could 
also be due to the number of copies of a particular DRMV (i.e. mutational load), prior exposure to 
treatment and patient adherence to treatment. Therefore, understanding factors which contribute to 
poor treatment outcomes in patients with DRMVs is a process, which may require several studies. 
 
In addition to understanding the complex effect of DRMVs on ART, NGS should become more 
feasible and accessible to clinicians caring for patients, especially in LMICs. Data analysis of NGS 
results is challenging and time consuming, partly due to the numerous sequence reads that are 
generated, requiring expert analysis [104]. NGS pipelines for data analysis such as Genome Detective 
[105], PASeq and HyDRA [104,106], which require minimal bioinformatics support are becoming 
increasingly relevant, in reducing the time and expertise required to analyse vast NGS data, as well as 
reducing variability in data analysis through automation. Moreover, considering that modern 
production scale NGS sequencers such as the Illumina NovaSeq 6000 produce approximately 6000 
GB of output data per run (illumina.com), storage of the large amounts of data is costly and might 
require high performance computing systems for data processing. These challenges may be addressed 
through combined efforts of scientists, data analysts and policy makers.   
 
6.2 Recommendations for policy 
Considering the increasing levels of NNRTI-associated drug resistance shown in chapters 3 and 4, 
and the significant association between NNRTI-DRMVs and ART failure in chapter 5, changing first-
line regimens from NNRTI- to DTG-based ART (i.e. TEE to TLD) ) may be the most logical public 
health response in South Africa, especially with neighbouring Botswana already using DTG in the 
public health sector [107]. However, considering the HIV burden in South Africa, existing ART 
program structures need to be able to support the policies which will be implemented in transitioning 
to TLD, i.e. the system in which the ART program will prioritize patients that initiate TLD is critical. 
Venter et al., in 2017 posed three scenarios for transitioning to DTG-based ART; i) a conservative 
approach, which includes starting new patients on DTG-based ART and transitioning all treatment 
experienced patients over a 3-year period, ii) a moderate approach, which includes starting new 
patients on DTG-based ART and transitioning treatment experienced patients over a 2-year period, iii) 
and an aggressive approach, which includes everyone receiving DTG-based ART within a year [108]. 
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A conservative approach in South Africa may be a better option, especially with such a high HIV 
burden. However, such an approach may cause undesirable delays in realizing the benefits of DTG. 
 
The WHO currently recommends use of DTG in first-line ART for treatment initiators, in second-line 
ART following exposure to first-line NNRTI, and in third-line ART with ritonavir-boosted darunavir 
and NRTIs [109]. DTG is therefore an integral part of ART programs for the future. Since DTG will 
continue being used in combination with other ARV drugs, maintaining virus susceptibility to NRTIs 
and PIs is important to the success of DTG. If mutations to other drug classes are not closely 
monitored, there is a risk of DTG being used as the only fully functional ARV drug in a regimen. 
Such a situation may result in DTG monotherapy, which must be avoided especially because of high 
rates of resistance selection which occur due to DTG-monotherapy [110]. Therefore, strategies which 
strengthen the HIV treatment cascade must be enforced to alleviate the extent of drug resistance to 
less potent drugs and to ensure the success of DTG-containing regimens. Furthermore, optimizing VL 
monitoring is crucial as more people are started on ART and are likely to transmit mutations by 
remaining on failing regimens for prolonged periods.  
 
A study from South Africa reported patients remaining on in-effective first-line ART regimens for of 
up to 27 months (interquartile range: 17 – 40) [55] before the ART regimen was changed. Strategic 
policy which enforces improvements in the coverage and quality of VL monitoring, management of 
virologic failure, and early switching of all patients showing virologic failure on NNRTI-based ART 
is recommended. It is important to continually attend to the objectives of the national strategic plan, 
which suggest the need for both routine and non-routine population and sentinel surveys, i.e. HIV 
prevalence surveys, antenatal surveys, and drug resistance surveys, to name a few [111]. These 
surveys are important to generate periodic estimates of HIV, but require coordination and routine 
implementation if they are to be effective. Facility based sentinel surveys (such as in antenatal 
women) may be easier to implement, but do not clearly reflect accurate measures of HIV in the 
general population. Despite the surveillance strategy used, implementation of surveys should be 
simplified, and should focus on timely monitoring that gives accurate measures within the general 
population, without adding further strain to the HIV treatment program. 
 
Future targeted interventions should be intensified for areas known to have high HIV prevalences, 
such as in KZN province. Moreover, as NGS slowly replaces Sanger sequencing as the preferred 
genotyping method, there should be considerations of the cost of setting up and maintaining NGS 
structures that are sustainable. Therefore, as studies address questions around the importance of 
DRMVs in policy decisions, strategies in making NGS available and accessible are also required. 
Centralizing NGS testing may help to reduce infrastructural costs and improve accessibility of NGS in 
most LMICs. Furthermore, as multiplexing of samples using NGS reduces the cost of genotyping 
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[68], centralizing NGS will help achieve the required numbers of samples in a relatively shorter time, 
reducing both the cost of the assay as well as the turn-around time of results. Therefore, in the context 
of HIVDR, it is important for policies to focus on enhancing HIVDR surveillance monitoring, 
implementing and enforcing viral load monitoring, as well as considering how to integrate NGS 
testing in informing treatment decisions, in a timely manner. 
 
6.3 Recommendations for future research 
Future research focusing on three main areas is required. Firstly, developing workable solutions for 
real-time monitoring and surveillance, secondly, assessment of treatment outcomes on DTG-
containing ART, and thirdly, continual assessment of the effect of pretreatment DRMVs on ART. If 
surveillance of drug resistance was being done regularly in South Africa, then the levels of resistance 
reported in chapters 3 and 4 could have contributed to the WHO’s recommendation for the use of 
DTG, as was suggested for Uganda, Zimbabwe, Namibia, Nicaragua, Guatemala and Argentina, all of 
which had reported pre-ART NNRTI resistance at ≥10%, by 2017 [53]. Prior to this study, only two 
South African studies reported levels of NNRTI-PDR close to 10%. These are the studies done on 
antenatal samples in 2016 [72] and in the Western Cape on adult ART naïve samples in 2017 [73], 
both of which reported NNRTI-PDR levels at 8.3%. Most sequences contributing to the high levels of 
NNRTI resistance (chapters 3 and 4) were from patients living in HIV hyper-endemic areas of the 
KZN province. This highlights the need for more research in understudied provinces in South Africa, 
with continual research in areas where HIV incidence rates are known to be high.  
 
The levels of resistance before and after the implementation of DTG based ART in the South African 
ART programme should be assessed to better inform future public health policy.  Therefore, studies 
specifically investigating and reporting mutation profiles in patients who fail DTG-based ART will be 
important in making decisions on future drug regimens. Further research is needed to investigate drug 
resistance in patients receiving DTG with multiple resistance to NRTIs, NNRTIs and PIs, to assess 
whether they still manage to maintain viral suppression on DTG. In addition, studies assessing how 
DRMVs contribute to treatment response, such as the individual and cumulative effect of DRMVs, 
drug-class mutational loads, clinically relevant detection thresholds, as well as DRMV patterns in 
patients with HIV co-infections, such as TB, are crucial. Among patients that fail treatment with no 
mutations (and have good ART adherence), further research on linked-mutations outside the pol gene; 
such as in the Gag cleavage sites [112,113], is required to determine the cause of failure. The study in 
chapter 5 had very few patients on PIs at ART failure, and could not investigate this linkage as 
sequencing was only done for the protease and reverse transcriptase genes. This also suggests the 
importance of HIV whole genome sequencing at ART failure, to investigate all possible linked 
mutations across the viral genome. 
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In conclusion, the work presented in this thesis provides the first evidence of high level NNRTI-PDR 
(>10%) in KZN and South Africa, and further evidence of virologic failure due to pre-ART NNRTI 
resistance in HIV/TB coinfected patients in KZN. South Africa needs to enroll another 3 million 
people on ART in addition to all those who become newly infected over the next few years, to 
effectively control the HIV epidemic. Furthermore, to minimize chances of these new infections, 
PrEP will need to be implemented and scaled up, preferably with the same ARVs which are used in 
first-line ART. However, for ART to be an effective treatment as prevention strategy, more potent 
ARVs need to be made readily available and accessible. In addition, it will be crucial to implement 
surveillance of HIVDR, further innovative research, and improve laboratory capacity to perform large 
scale HIVDR testing. Whilst the response to these research findings may include modification of the 
standard first-line ART regimen, these findings also present a broader public health implication for 
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Table S1. Estimated prevalence of pre-treatment HIV drug resistance by sex and age  
 Pre-treatment HIVDR Prevalence                
             Female                Male               Total 
 n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) 
Study A       
15-24 years 13/121 10.7 (5.8-17.7) 2/24 8.3 (1.0-27.0) 15/145 10.3 (5.9-16.5) 
25-34 years 17/162 10.5 (6.2-16.3) 1/55 1.8 (0.0-9.7) 18/217 8.3 (5.0-12.8) 
35-44 years 7/84 8.3 (3.4-16.4) 3/41 7.3 (1.5-19.9) 10/125 8.0 (3.9-14.2) 
45+ years 8/88 9.1 (4.0-17.1) 5/36 13.9 (4.7-29.5) 13/124 10.5 (5.7-17.3) 
Study Ba       
15-24 years 34/248 14.1 (8.6-19.5) 6/66 7.9 (0.9-14.9) 40/314 12.2 (7.9-16.5) 
25-34 years 52/299 17.0 (11.9-22.1) 20/208 8.1 (4.2-12.0) 72/507 11.9 (8.6-15.1) 
35-44 years 22/203 8.5 (4.4-12.6) 8/116 7.5 (1.8-13.2) 30/319 8.0 (4.5-11.5) 
45+ years 9/64 11.2 (1.1-21.3) 5/30 15.0 (1.2-28.7) 14/94 13.0 (4.9-21.1) 














Table S2. Most frequently observed patterns of surveillance drug resistance 
mutations 
Mutations Study A Study B Overall 
K103NS 24 (42.9) 76 (48.7) 100 (47.2) 
M46IL 1 (1.8) 11 (7.1) 12 (5.7) 
V106AM 1 (1.8) 8 (5.1) 9 (4.2) 
M184V, K103NS, P225H 4 (7.1) 3 (1.9) 7 (3.3) 
M184V, K103NS 3 (5.4) 2 (1.3) 5 (2.4) 
G190AS 1 (1.8) 3 (1.9) 4 (1.9) 
K101EP 0 3 (1.9) 3 (1.4) 
Y181C 0 3 (1.9) 3 (1.4) 
M230L 0 3 (1.9) 3 (1.4) 
K103NS, P225H 1 (1.8) 2 (1.3) 3 (1.4) 
M41L 1 (1.8) 2 (1.3) 3 (1.4) 
Other 20 (35.7) 40 (25.6) 60 (28.3) 
Total 56 156 212 




























Description on timing of recruitment and ascertainment of antiretroviral 
therapy status for the two population-based studies 
 
Study A 
In 2013, samples were collected between 22 January and 27 November, and the 
median date of sample collection was 5 June 2013, whilst in 2014, samples were 
collected between 21 January and 30 November, and the median date of sample 
collection was 18 July 2014.  
 
To complement the population-based surveillance research, the Africa Health 
Research Institute (formerly Africa Centre for Population Health) has maintained a 
clinical database for all people treated with antiretroviral therapy (ART) at 17 primary 
health care clinics and one district hospital in the Hlabisa sub-district. This database 
holds records for people who have received ART since 2004, the start of the public 
sector ART roll-out. Data from the clinical database are linked with the population-
based surveillance data by deterministic record linkage (using the unique South 
African ID number, if recorded) or probabilistic record linkage (using first name, 
surname, date of birth, and sex). The database has a variable for date of ART 
initiation, so for the purposes of this analysis, we could determine whether there had 
been any use of ART (for treatment) prior to the date of surveillance sample 
collection used for genotypic resistance testing. The clinical database does not hold 
information on antiretroviral regimens for prevention of mother-to-child transmission 
(pMTCT) prior to 2013, i.e. single-dose nevirapine regimens with or without 
zidovudine and/or single-dose tenofovir/emtricitabine. It also does not hold 
information on use of antiretrovirals for pre-exposure or post-exposure prophylaxis, 
but use in these circumstances was very low over the study period. The database 
does not hold information about people who accessed ART in the public sector 
outside Hlabisa sub-district. The database also does not hold information about 
people who accessed ART in the private sector. Private sector ART use is low in the 
study area, due to the low levels of private health insurance and good access to ART 
in the public sector.  
 
Study B 
In 2014, samples were collected between 7 January and 12 December, and the 
median date of sample collection was 26 August 2014, whilst in 2015, samples were 
collected between between 4 January and 6 December, and the median date of 
sample collection was 28 April 2015. 
 
In the HIV Incidence Provincial Surveillance System (HIPSS), the survey included 
questions about antiretroviral use, which were asked to any participant who reported 






you need to take ARVs?’ If the answer to this question was yes, then the participant 
was asked ‘Are you still on ARVs?’ In addition, female participants were asked the 
question, ‘Have you ever been pregnant while you were HIV positive?’ If the answer 
to this was yes, they were asked ‘Which of the following services did you access 
while HIV positive and pregnant?’ One option for this question was ‘Medication to 
prevent mother-to-child transmission’. The survey did not ask questions about use of 
antiretrovirals for pre-exposure or post-exposure prophylaxis. 
From these questions, we determined whether there had been any use of 
antiretrovirals for treatment or pMTCT prior to the date of sample collection.  
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Supplementary Table 2 Search strategy in OVID Medline 
# Searches Results 
1 exp HIV/ 93755 
2 HIV·mp [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, 
synonyms] 
304579 
3 1 or 2 304579 
4 South Africa/ 37442 
5 South Africa·mp [mp=title, abstract, original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms] 
42835 
6 4 or 5 42835 
7 exp Drug Resistance, Viral/ 45943 
8 exp Sequence Analysis/ 340523 
9 Genes, pol/ 1114 
10 Genotyping Techniques/ 4991 
11 exp Molecular Epidemiology/ 33833 
12 exp Genetic Variation/ 998697 
13 phylogenetic*·mp [mp=title, abstract, original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms] 
105550 
14 resistan*·mp [mp=title, abstract, original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms] 
882013 
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 2062123 

























Supplementary Table 3 List of WHO 2009 surveillance drug-resistance mutations (SDRMs), with eight 
additional tenofovir resistance-associated mutations (TRAMs) 
NRTI mutations NNRTI mutations PI mutations 
M41L L100I L23I 
A62V K101E L24I 
K65R K101P D30N 
K65N K103N V32I 
D67N K103S M46I 
D67G V106M M46L 
D67E V106A I47V 
S68G V179F I47A 
S68D Y181C G48V 
S68N Y181I G48M 
T69D Y181V I50V 
T69ins Y188L I50L 
K70R Y188H F53L 
K70E Y188C F53Y 
K70Q G190A I54V 
K70T G190S I54L 
L74V G190E I54M 
L74I P225H I54A 
V75M M230L I54T 
V75T  I54S 
V75A  G73S 
V75S  G73T 
V75L  G73C 
F77L  G73A 
Y115F  L76V 
F116Y  V82A 
Q151M  V82T 
M184V  V82F 
M184I  V82S 
L210W  V82C 
L215Y  V82M 
L215F  V82L 
L215I  N83D 
L215S  I84V 
L215C  I84A 
L215D  I84C 
L215V  I85V 
L215E  N88D 
K219Q  N88S 
K219E  L90M 
K219N   
K219R   
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor           
 












Supplementary Table 4 Details of excluded studies 
Source Sampling 
years 
Province(s) Study type Study population Number of HIV-1 pol 
sequences 
Reason for exclusion 
Abrahams1 2004-2005 KZN Acute infection cohort Adults with acute HIV infection 5 <10 pol sequences  
Eshleman2 1993-2001 Not stated Laboratory validation 
study 
Asymptomatic blood donors 15 Samples collected prior to 2000 
Horaa 2007-2008 Not stated Unpublished  Not known 6 <10 pol sequences 
Iweriebor3 2008 LP Drug resistance study ART-naïve adult 1 <10 pol sequences 
Li4 2001-2005 GT Prevention of mother-
to-child transmission 
study 
ART-naïve women prior to 
single dose nevirapine 
99 Targeted sequencing for K65R 
mutation only 
Liu5 Not stated KZN Acute infection cohort Adults with acute HIV infection 9 <10 pol sequences 
Musyoki6 2009 LP Case report 
(recombinant strain) 
Single ART-naïve female 1 <10 pol sequences 
Orrell7 2003-2006 WC PDR study ART-naïve adults 120 Sequences not obtained   
Rademeyer8 2007 KZN Acute infection cohort Adults with acute HIV infection 4 <10 pol sequences 
Rousseau9 2000-2006 KZN Chronic infection 
cohort 
ART-naïve adults receiving 
HIV care (and specifically 
women in antenatal care) 
248 Sequences duplicated from Matthews 
Van Harmelen10 Not stated KZN, WC Acute and chronic 
infection cohorts 
Recently and chronically 
infected adults 
4 <10 pol sequences 
Wilkinson11 1998-2004 WC Laboratory samples 
from multiple sources 
HIV-positive adults (multiple 
cohorts) 
7 <10 pol sequences   
Wright12 2003-2006 KZN Chronic infection 
cohort 
ART-naïve adults 405 Protease sequence only (no RT 
sequences) 
Wright13 2008-2009 KZN Acute infection cohort Adults with acute HIV infection 32 Protease sequence only (no RT 
sequences) 
 
ART, antiretroviral therapy; EC, Eastern Cape; FS, Free State; GT, Gauteng; KZN, KwaZulu-Natal; LP, Limpopo; MP, Mpumalanga; NC, Northern Cape; NS, not stated; NW, North West; PDR, pretreatment drug 
resistance; WC, Western Cape  
 
a Unpublished  
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Supplementary Table 5 Additional details of included datasets 
Dataset ID  Author Urban/rural Agesa CD4+ cell count 
(cells/μL) 
Recent vs chronic infection Specimen type Sequencing 
methodb 
VL criterion for 
sequencing 
(copies/mL) 
1 Bessong Rural 20-53 yrs Median 334 - Plasma In house  NS 
2 Bessong Rural 20-53 yrs NS - Plasma In house NS 
3 Chimukangara Rural 15-88 yrs NS Previous negative HIV ELISA 
(surveillance) 
DBS In house 10 000 
4 Chimukangara Rural 16-78 yrs NS Previous negative HIV ELISA 
(surveillance) 
DBS In house 10 000 
5 Chimukangara Rural 15-49 yrs NS - Plasma In house 1000 
6 Gordon Urban & rural Mean 38 yrs Mean 366 - Plasma/DBS Viroseq NS 
7 Hamers Urban & rural - Median 94-140c - Plasma In house NS 
8 Huang Urban & rural Mean 36 yrs Mean 271 - Plasma Viroseq/In 
house 
NS 
9 Hunt Urban & rural 18-24 yrs NS BED assay Serum In house NS 
10 Hunt Urban & rural 18-21 yrs NS BED assay Serum In house NS 
11 Hunt Urban & rural 18-22 yrs NS BED assay Serum In house NS 
12 Hunt Urban & rural 18-24 yrs NS BED assay Serum In house NS 
13 Hunt Urban & rural 18-21 yrs NS BED assay Serum In house NS 
14 Hunt Urban & rural Median 19 yrs NS - NS - NS 
15 Hunt Urban & rural <25 yrs NS - NS - NS 
16 Hunt Urban & rural <21 yrs NS - NS - NS 
17 Iweriebor Urban 6-52 yrs NS - Plasma In house NS 
18 Jacobs Urban NS NS - Plasma In house NS 
19 Jacobs Urban 21-50 yrs Mean 375 - Plasma In house NS 
20 Manasa Rural 18-57 yrs Median 413 Previous negative HIV ELISA 
(surveillance) 
Plasma In house NS 
21 Manasa Rural Mean 34 yrs NS Previous negative HIV ELISA 
(surveillance) 
DBS In house 10 000 
22 Manasa Rural Mean 34 yrs NS Previous negative HIV ELISA 
(surveillance) 
DBS In house 10 000 
23 Matthews Urban NS Median 387 - Plasma In house NS 
24 Msimanga Rural 16-41 yrs Mean 450 - Plasma In house NS 
25 Musyoki Urban NS NS - Plasma In house 100 000 












27 Papathanasopoulos Urban 21-55 yrs Median 403 - Plasma In house NS 
28 Parboosing Urban 15-20 yrs NS - Plasma Viroseq NS 
29 Parikh Urban 18-40 yrs NS - Plasma Viroseq/In 
house 
200 
30 Pillay Urban NS Median 479 - Plasma In house NS 
31 Pillay Urban & rural 18-21 yrs NS - Serum In house NS 
32 Pillay Urban & rural 18-21 yrs NS - Serum In house NS 
33 Seoighe Urban NS NS - NS In house NS 
34 Steegen Urban & rural Median 34 yrs Median 149 - Plasma In house NS 
35 Treurnicht Urban NS Median 558 Acute infectiond Plasma  In house NS 
36 van Zyl Urban & rural Mean 34 yrs Median 337 - Plasma In house NS 
37 Wilkinson Urban & rural 21-61 yrs NS - Plasma In house NS 
38 Wilkinson Urban & rural 21-61 yrs NS - Plasma In house NS 
BED, BED IgG-Capture Enzyme Immunoassay; DBS, dried blood spots; ELISA, enzyme-linked immunosorbent assay; NS, not stated; VL, viral load 
 
a Ages are stated as range, unless otherwise stated; b All in-house sequencing systems used Sanger sequencing methods; c Range of median CD4+ cell count across three South African study sites; d Acute infection 
defined as the detection of HIV-1 antibodies within five months of a previously negative HIV-1 test, or evidence of HIV-1 viral replication in the absence of HIV-1 antibodies  
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Supplementary Table 6 Details of publications and HIV sequence accession numbers 
Dataset ID Source Journal PMID GenBank accession numbers PopSet 
1 Bessong AIDS Res Hum Retro 15665650 AY510031-AY510056 40846255, 40846281 
2 Bessong AIDS Res Hum Retro 17209775 DQ222243-DQ222317 77812531, 77812451 
3 Chimukangara AIDS Res Hum Retro 30430843 NA NA 
4 Chimukangara AIDS Res Hum Retro 30430843 NA NA 
5 Chimukangara AIDS Res Hum Retro 30430843 NA NA 
6 Gordon J Virol 12551997 AY136957-AY137008, 
AY196498-AY196517 
28557514 
7 Hamers Lancet Infect Dis 21802367 HQ994353-HQ994917 NA 
8 Huang Antivir Ther 19918101 KT736966-KT737213 1004353616 
9 Hunt Clin Infect Dis 22544199 NA  NA 
10 Hunt Clin Infect Dis 22544199 NA  NA 
11 Hunt Clin Infect Dis 22544199 NA  NA 
12 Hunt Clin Infect Dis 22544199 NA  NA 
13 Hunt Clin Infect Dis 22544199 NA  NA 
14 Hunt Comm Dis Surv Bull NA KY060489-KY060546, 
KY060662-KY060711 
NA 




KY061063-KY061127,                                                                       
NA 







17 Iweriebor Arch Virol 22189822 GU201754-GU201826 284434133, 282895359 
18 Jacobs AIDS Res Hum Retro 18593350 EF602162-EF602301 148612215, 148612233, 149394577 
19 Jacobs PLoS ONE 24609015 KF793121-KF793185 NA 
20 Manasa AIDS Res Hum Retro 22251009 JN664970-JN665041 374094941 
21 Manasa AIDS Res Hum Retro 27002368 NA NA 
22 Manasa AIDS Res Hum Retro 27002368 NA NA 






28 Parboosing  56 56 56 56 
29 Parikh  353 352 352 352 
30 Pillay  37 37 0 0 
31 Pillay  58 58 0 0 
32 Pillay 43 43 0 0 
33 Seoighe  300 300 0 0 
34 Steegen  277 277 277 277 
35 Treurnicht  15 15 15 15 
36 van Zyl  59 59 59 59 
37 Wilkinson  29 29 29 29 
38 Wilkinson 32 32 32 32 




Supplementary Table 8 Patterns of single class, dual class and triple class resistance in HIV-1 sequences 
with any drug resistance mutation 
Pattern of resistance Number of sequences Proportion (95% CI) 
Single class resistance 389 81·4 (77·6-84·8) 
NRTI 50 10·5 (7·9-13·6) 
NNRTI 289 60·5 (55·9-64·9) 
PI  50 10·5 (7·9-13·6) 
Dual class resistance 87 18·2 (14·8-22·0) 
NRTI/NNRTI 79 16·5 (13·3-20·2) 
NRTI/PI 4 0·8 (0·2-2·1) 
NNRTI/PI 4 0·8 (0·2-2·1) 
Triple class resistance 2 0·4 (0·1-1·5) 
NRTI/NNRTI/PI 2 0·4 (0·1-1·5) 
 

















Supplementary Table 9 Pooled prevalence of specific non-nucleoside reverse transcriptase inhibitor 
resistance mutations  
Mutation n % of sequences with 
any DRM (n=478) 
% of all sequences 
(n=6880) 
L100I 5 1·05 0·07 
L101E 27 5·65 0·39 
L101P 2 0·42 0·03 
K103N 271 56·69 3·94 
K103S 7 1·46 0·10 
V106M 46 9·62 0·67 
V106A 1 0·21 0·01 
V179F 0 0·00 0·00 
Y181C 34 7·11 0·49 
Y181I 0 0·00 0·00 
Y181V 0 0·00 0·00 
Y188L 11 2·30 0·16 
Y188H 0 0·00 0·00 
Y188C 5 1·05 0·07 
G190A 25 5·23 0·36 
G190S 2 0·42 0·03 
G190E 0 0·00 0·00 
P225H 23 4·81 0·33 
M230L 6 1·26 0·09 
 

































Supplementary Table 10 Pooled prevalence of specific drug resistance mutations by time period 
Drug resistance mutations 2000-2008 
(N = 2480) 
 2009-2012 
(N = 2219) 
 2013-2016 




n % (95% CI) 
 
n % (95% CI) 
 
n % (95% CI)  
NRTI resistance mutations          
M184VI 4 0·16 (0·04-0·41) 
 
20 0·90 (0·55-1·39) 
 
47 2·15 (1·59-2·86) <0·001 
TRAMs 3 0·12 (0·02-0·35) 
 
11 0·50 (0·25-0·89) 
 
23 1·05 (0·67-1·58) <0·001 
TAMs 10 0·40 (0·19-0·74) 
 
10 0·45 (0·22-0·83) 
 
19 0·87 (0·53-1·36) 0·071 
L74V or Y115F 0 - 
 
2 0·09 (0·01-0·33) 
 
7 0·32 (0·13-0·66) 0·008 




   
K101EP 5 0·20 (0·06-0·47) 
 
9 0·41 (0·19-0·77) 
 
15 0·69 (0·39-1·13) 0.038 
K103NS 37 1·49 (1·05-2·05) 
 
81 3·65 (2·91-4·52) 
 
160 7·34 (6·28-8·51) <0.001 
V106AM 2 0·08 (0·01-0·29) 
 
17 0·77 (0·45-1·22) 
 
28 1·28 (0·85-1·85) <0.001 
Y181C 13 0·52 (0·28-0·89) 
 
10 0·45 (0·22-0·83) 
 
11 0·50 (0·25-0·90) 0.934 
G190ASE 7 0·28 (0·11-0·58) 
 
9 0·41 (0·19-0·77) 
 
11 0·50 (0·25-0·90) 0.477 
CI, confidence interval; TAMs, thymidine analogue mutations; TRAMs, tenofovir resistance-associated mutations 
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Supplementary Table 11 Pooled prevalence of specific nucleoside reverse transcriptase inhibitor 
resistance mutations  
Mutation n % of sequences with 
any DRM (n=478) 
% of all sequences 
(n=6880) 
M41L 14 2·93 0·20 
A62V 10 2·09 0·15 
K65R 21 4·39 0·31 
K65N 0 0·00 0·00 
D67N 10 2·09 0·15 
D67G 4 0·84 0·06 
D67E 2 0·42 0·03 
S68G 0 0·00 0·00 
S68D 0 0·00 0·00 
S68N 0 0·00 0·00 
T69D 4 0·84 0·06 
T69ins 0 0·00 0·00 
K70R 8 1·67 0·12 
K70E 4 0·84 0·06 
K70Q 0 0·00 0·00 
K70T 2 0·42 0·03 
L74V 6 1·26 0·09 
L74I 1 0·21 0·01 
V75M 0 0·00 0·00 
V75T 0 0·00 0·00 
V75A 2 0·42 0·03 
V75S 0 0·00 0·00 
V75L 0 0·00 0·00 
F77Le 0 0·00 0·00 
Y115F 4 0·84 0·06 
F116Y 1 0·21 0·01 
Q151M 1 0·21 0·01 
M184V 65 13·60 0·94 
M184I 6 1·26 0·09 
L210W 3 0·63 0·04 
L215Y 2 0·42 0·03 
L215F 3 0·63 0·04 
L215I 0 0·00 0·00 
L215S 0 0·00 0·00 
L215C 0 0·00 0·00 
L215D 2 0·42 0·03 
L215V 1 0·21 0·01 
L215E 1 0·21 0·01 
K219Q 3 0·63 0·04 
K219E 6 1·26 0·09 
K219N 2 0·42 0·03 
K219R 6 1·26 0·09 
 







Supplementary Table 12 Pooled prevalence of specific protease inhibitor resistance mutations  
Mutation n % of sequences with 
any DRM (n=478) 
% of all sequences 
(n=6294)a 
L23I 1 0·21 0·02 
L24I 1 0·21 0·02 
D30N 0 0·00 0·00 
V32I 1 0·21 0·02 
M46I 19 3·97 0·34 
M46L 16 3·35 0·28 
I47V 2 0·42 0·04 
I47A 0 0·00 0·00 
G48V 0 0·00 0·00 
G48M 0 0·00 0·00 
I50V 1 0·21 0·02 
I50L 0 0·00 0·00 
F53L 0 0·00 0·00 
F53Y 1 0·21 0·02 
I54V 0 0·00 0·00 
I54L 0 0·00 0·00 
I54M 0 0·00 0·00 
I54A 0 0·00 0·00 
I54T 1 0·21 0·02 
I54S 0 0·00 0·00 
G73S 1 0·21 0·02 
G73T 0 0·00 0·00 
G73C 0 0·00 0·00 
G73A 0 0·00 0·00 
L76V 0 0·00 0·00 
V82A 1 0·21 0·02 
V82T 0 0·00 0·00 
V82F 2 0·42 0·04 
V82S 0 0·00 0·00 
V82C 0 0·00 0·00 
V82M 0 0·00 0·00 
V82L 0 0·00 0·00 
N83D 1 0·21 0·02 
I84V 0 0·00 0·00 
I84A 0 0·00 0·00 
I84C 0 0·00 0·00 
I85V 6 1·26 0·11 
N88D 0 0·00 0·00 
N88S 1 0·21 0·02 
L90M 5 1·05 0·09 
 
DRM, surveillance drug resistance mutation 
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Appendix 4 Supplementary material to manuscript entitled “Impact of HIV pretreatment drug 
























Table S1 Subset of patients receiving PI-based ART at time of virologic failure 








SAP026 ABC+AZT+LPV/r 04/02/2010 11/11/2010 9.3 None 




SAP100 TDF+AZT+LPV/r 05/08/2010 07/06/2012 22.4 K103N 
SAP194 ABC+TDF+LPV/r 14/10/2008 21/10/2008 0.2 None 
SAP200 TDF+AZT+LPV/r 08/12/2008 05/01/2009 0.9 None 
SAP206 ABC+AZT+LPV/r 01/06/2009 06/07/2009 1.2 None 
SAP221 TDF+AZT+LPV/r 16/04/2009 27/02/2012 35.9 None 
ABC, abacavir; ART, antiretroviral therapy; AZT, zidovudine; ddI, didanosine; ID, identification; 
LPV/r, ritonavir-boosted lopinavir; TDF, tenofovir 
 






















Table S2 Associations between demographic and clinical characteristics with ART failure 
 p-value Odds ratio 95% confidence interval 
Continuous variables    
  Age 0.47 0.986 0.948 – 1.024 
  CD4 count (cells/mm3) 0.22 0.998 0.995 – 1.001 
  Viral load (log10 copies/mL) 0.58 0.880 0.566 – 1.374 
Categorical variables    
  Sex 0.41 1.362 0.669 – 2.828 
ART, antiretroviral therapy mm3, CD4, cluster of differentiation 4; cubic millimeter; mL, milliliter 
 
Note: Exact logistic regression was used for continuous variables and Fisher’s exact test for 


























Table S3 Subset of case samples with DRMVs selected for between pre-ART and ART failure time 
points 
Sample ID Pre-ART VL 
(copies/ml) 
ART failure VL 
(copies/ml) 
DRMs at pre-ART 
(frequency in %) 
DRMs at ART failure 
(frequency in %) 






















V106M (99.6)  
V179D (26) 
M184V (96.8) 







ART, antiretroviral therapy; DRMs, drug resistance mutations; ID, identification; VL, viral load  
Note: Text in bold represents mutations that were selected for between pre-ART and ART failure 
time-points 
 
 
 
  
 1 
 
